Hostname: page-component-7b9c58cd5d-bslzr Total loading time: 0.001 Render date: 2025-03-15T17:51:19.604Z Has data issue: false hasContentIssue false

Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues

Published online by Cambridge University Press:  28 January 2009

Rongbao Zhao
Affiliation:
Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Larry H. Matherly
Affiliation:
Department of Pharmacology and the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
I. David Goldman*
Affiliation:
Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
*
*Corresponding author: I. David Goldman, Cancer Center, Albert Einstein College of Medicine, Chanin Two, 1300 Morris Park Avenue, Bronx, NY 10461, USA. Tel: +1 718 430 2302; Fax: +1 718 430 8550; E-mail: igoldman@aecom.yu.edu
Rights & Permissions [Opens in a new window]

Abstract

Members of the family of B9 vitamins are commonly known as folates. They are derived entirely from dietary sources and are key one-carbon donors required for de novo nucleotide and methionine synthesis. These highly hydrophilic molecules use several genetically distinct and functionally diverse transport systems to enter cells: the reduced folate carrier, the proton-coupled folate transporter and the folate receptors. Each plays a unique role in mediating folate transport across epithelia and into systemic tissues. The mechanism of intestinal folate absorption was recently uncovered, revealing the genetic basis for the autosomal recessive disorder hereditary folate malabsorption, which results from loss-of-function mutations in the proton-coupled folate transporter gene. It is therefore now possible to piece together how these folate transporters contribute, both individually and collectively, to folate homeostasis in humans. This review focuses on the physiological roles of the major folate transporters, with a brief consideration of their impact on the pharmacological activities of antifolates.

Type
Review Article
Copyright
Copyright © Cambridge University Press 2009

Folates are a family of B9 vitamins that play a critical role in key biosynthetic processes in mammalian cells. These one-carbon donors are required for purine nucleotide and thymidylate synthesis and hence, are essential for the de novo production of RNA and DNA. Folates are also required for vitamin-B12-dependent synthesis of methionine, a precursor of S-adenosylmethionine, which is required for methylation of DNA, histones, lipids and neurotransmitters (Ref. Reference Stokstad, Picciano and Stokstad1). Mammalian cells, unlike bacteria, do not have the metabolic machinery to synthesise folates. Hence, folate requirements must be met entirely from dietary sources. Traditionally, folates were derived from foods such as liver and dark green leafy vegetables. The recent commercial fortification of cereals, grains and bread with folic acid now represents an important source of folates. This has resulted in a rise in folate levels in tissues and blood (Ref. Reference Jacques2). Because of the hydrophilic nature of the charged folate molecule, there is minimal passive diffusion across cell membranes. Rather, highly specific transporters are required to mediate intestinal folate absorption and the transport of folates into systemic tissues. However, despite the importance of these vitamins and their membrane transport, aspects of folate physiology, particularly relating to their transport, were uncharacterised and/or misunderstood until recently.

There is considerable information, acquired over many decades, regarding the properties of two folate transporters. (1) The reduced folate carrier (RFC; official gene symbol SLC19A1), a member of the superfamily of solute carriers, is an anionic exchanger and a major route of delivery of folates to systemic tissues at physiological pH (Refs Reference Matherly and Goldman3, Reference Matherly, Hou and Deng4). (2) Two folate receptors (FRα and FRβ), embedded in the cell membrane by a glycosylphosphoinositol (GPI) anchor, transport folates via receptor-mediated endocytosis at neutral to mildly acidic pH (Refs Reference Kamen and Smith5, Reference Salazar and Ratnam6). Recently, a third folate transporter was identified – the proton-coupled folate transporter (PCFT; SLC46A1). PCFT also belongs to the superfamily of solute carriers and functions optimally at low pH (Refs Reference Qiu7, Reference Zhao and Goldman8). PCFT accounts for the low-pH folate transport activity in many normal and malignant tissues, most notably the small intestine. The critical role that PCFT plays in intestinal folate absorption was established by the demonstration of loss-of-function mutations in this gene in patients with hereditary folate malabsorption (HFM) (Refs Reference Qiu7, Reference Zhao9, Reference Min10).

Structural analogues of folate compounds have been used for treating cancer and autoimmune diseases (Refs Reference Wessels, Huizinga and Guchelaar11, Reference Zhao and Goldman12). These include methotrexate and, more recently, pemetrexed, (Refs Reference Zhao and Goldman12, Reference Chattopadhyay, Moran and Goldman13). These agents utilise the same transporters as physiological folates to enter tumour cells. Transport is an important determinant of antifolate activity, and impaired transport is a key mechanism of drug resistance (Refs Reference Zhao and Goldman12, Reference Chattopadhyay, Moran and Goldman13). This review considers how these three transport systems contribute both individually and collectively to folate homeostasis in man and to delivery of antifolates in the treatment of cancer.

Tetrahydrofolate cofactors: interconversions and utilisation in folate-dependent biochemical reactions

The folate molecule consists of a pteridine moiety with A and B rings linked at carbon 6 by a methylene bridge to p-aminobenzoylglutamic acid (Fig. 1). ‘Folate’ is a generic term for members of the B9 family of vitamins and will be used as such in this review. The parent structure is folic acid, a pharmacological agent not found in nature. Because of its stability, folic acid has been used as a folate source in cell culture medium and in vitamins; within cells, it is reduced at the B ring, first to dihydrofolate (DHF) and then to tetrahydrofolate (THF) (Fig. 1). Folic acid is also used to discriminate between folate transport routes, for which it has markedly different affinities. THF is a good substrate for the enzyme, folylpolyglutamate synthetase (FPGS), which progressively adds glutamate molecules at the gamma carboxyl residue through an amide bond to form glutamate-peptide chains of varying length (Fig. 1). THF polyglutamates associate with methyl, formyl, methylene or methenyl one-carbon moieties at the N5 and/or N10 positions, which serve as one-carbon donors in biosynthetic reactions (Ref. Reference Stokstad, Picciano and Stokstad1). The folate polyglutamate derivatives are, with few exceptions, the preferred substrates for one-carbon transfer reactions over their nonpolyglutamate (hereafter, designated ‘monoglutamate’) precursors (Ref. Reference Shane14).

Figure 1. Structures of representative folate compounds. (a) Folic acid is reduced to dihydrofolic acid at positions 7 and 8 of the B ring, which is in turn reduced to tetrahydrofolic acid at positions 5 and 6 in reactions mediated by dihydrofolate reductase (DHFR). Endogenous folic acid is not found in cells; its presence is related to the consumption of folic acid added to cereals, grains and vitamins. The major oxidised folate in cells is dihydrofolic acid. 5-Methyltetrahydrofolic acid (5-methylTHF) is the major dietary form and the dominant folate found in blood. It is formed endogenously by the reduction of 5,10-methylene-tetrahydrofolic acid (5,10-methyleneTHF). Tetrahydrofolate (THF) is generated upon utilisation of 5-methylTHF in methionine synthesis and 10-formylTHF in purine synthesis. These relationships are depicted in Figure 2. The two carboxyl groups of the glutamate moiety are fully ionised at physiological pH. (b) Structure of 5-methylTHF tetraglutamate, which is one of the 5-methylTHF forms found in nature and in mammalian cells. It is a polyanion and a very poor substrate for folate transporters and multidrug-resistance-associated proteins.

The predominant natural folate in the diet and blood of humans and rodents is 5-methylTHF (Fig. 1). Utilisation of this form in cells begins with the transfer of a methyl group to homocysteine, in a vitamin-B12-dependent reaction mediated by methionine synthase, to form methionine (Fig. 2). The unsubstituted THF released then reacts with formate (via 10-formylTHF synthetase) to produce 10-formylTHF, which donates two carbons to the synthesis of the purine ring in reactions mediated first by β-glycinamide ribonucleotide (GAR) transformylase and then by 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR) transformylase. 10-FormylTHF also undergoes dehydration to 5,10-methenylTHF, which in turn is reduced to 5,10-methyleneTHF. 5,10-MethyleneTHF is also formed from THF by serinehydroxymethyltransferase, which interconverts serine to glycine. 5,10-MethyleneTHF is reduced in an irreversible reaction by 5,10-methyleneTHF reductase (MTHFR) to 5-methylTHF. 5,10-MethyleneTHF is required for de novo synthesis of thymidylate, catalysed by thymidylate synthase, in which a one-carbon moiety is transferred to deoxyuridylate along with a reducing equivalent from the pteridine B ring. This results in oxidation of the THF moiety to DHF. Because of its rapidity and irreversibility, this reaction has the potential to deplete cellular THF cofactors, which rapidly interconvert to 5,10-methyleneTHF by mass action as this folate is oxidised to DHF. However, THF cofactor levels are maintained because of the rapid reduction of DHF to THF, mediated by dihydrofolate reductase (DHFR) (Fig. 2). When DHFR is inhibited by methotrexate, aminopterin or the more recently developed drug PT523, there is rapid interconversion of THF cofactors to DHF, resulting in cessation of one-carbon-dependent processes (Refs Reference Zhao and Goldman12, Reference Matherly15, Reference Seither16).

Figure 2. Folate metabolic pathways. 5-MethylTHF enters the metabolic cycle following transport into cells where, with homocysteine, it is utilised in the synthesis of methionine mediated by methionine synthase and vitamin B12. The tetrahydrofolate (THF) product then acquires a carbon from formate or serine, at the N5 or N10 positions, which, through a series of interconversions, results in several other folate forms that provide carbons for purine, thymidylate and methionine synthesis. Abbreviations: AICAR, 5-amino-4-imidazolecarboxamide ribonucleotide; GAR, β-glycinamide ribonucleotide; SHMT, serinehydroxymethyltransferase.

The folate transporters

The reduced folate carrier

RFC (SLC19A1) was the first folate transporter described at the kinetic and thermodynamic levels (Refs Reference Matherly and Goldman3, Reference Goldman, Lichtenstein and Oliverio17, Reference Goldman and Matherly18, Reference Sirotnak and Tolner19). The gene that encodes human RFC (SLC19A1) is located on chromosome 21q22.3. The K m for 5-methylTHF, 5-formylTHF and methotrexate influx mediated by RFC is in the 2–7 µM range; the K m for PT523 is much lower. RFC has a very low affinity for folic acid (K i ~150–200 µM). The high affinity of RFC for PT523, its very low affinity for folic acid, and its neutral pH optimum clearly distinguish this carrier from PCFT. Methotrexate is frequently used to characterise RFC-mediated transport because it is not metabolised over short intervals and because of the ease and accuracy of influx determinations and distinguishing between free and tightly bound drug within cells (Ref. Reference Goldman, Lichtenstein and Oliverio17).

RFC generates only small transmembrane chemical gradients. However, folates are negatively charged because of the two glutamate carboxyl groups that are fully ionised at physiological pH (Fig. 1). When this is considered within the context of the membrane potential, RFC actually produces a substantial electrochemical potential difference for folates across cell membranes (Ref. Reference Goldman, Lichtenstein and Oliverio17). The energy source for this uphill process is unique. RFC function is not directly linked to ATP hydrolysis and it is neither Na+- nor H+-dependent (Refs Reference Henderson and Zevely20, Reference Goldman21). Rather, RFC-mediated transport is highly sensitive to the transmembrane anion gradient, in particular, the organic phosphate gradient (Refs Reference Henderson and Zevely20, Reference Goldman21). Organic phosphates are highly concentrated in cells where they are synthesised in ATP-dependent reactions and are largely retained. Their resulting asymmetrical distribution across cell membranes provides the driving force for RFC-mediated uphill transport of folates into cells (Ref. Reference Goldman21).

The most substantive support for this model comes from studies on thiamine transport and metabolism. There are two other members of the SLC19 family, SLC19A2 and SLC19A3, with ∼40% homology to RFC (Refs Reference Labay22, Reference Fleming23, Reference Diaz24, Reference Dutta25, Reference Rajgopal26). However, both are thiamine – not folate – transporters. Neither does RFC transport thiamine. However, after thiamine is transported into cells, it is converted to thiamine pyrophosphate and thiamine monophosphate (Ref. Reference Rindi and Laforenza27); both are transported by RFC (K i values of ∼25 µM and 32 µM, respectively) (Refs Reference Zhao28, Reference Zhao, Gao and Goldman29). When cells are exposed to thiamine, these phosphorylated derivatives accumulate intracellularly. However, the higher the level of RFC expression, the lower the level of cellular accumulation of thiamine pyrophosphate, because of enhanced export mediated by RFC. Likewise, when cells are loaded with methotrexate, accumulation of the phosphorylated derivatives of thiamine is enhanced as a result of methotrexate inhibition of their export by RFC (Ref. Reference Zhao28). These observations can only be explained if methotrexate and phosphorylated derivatives of thiamine use the same carrier – RFC. These interactions between thiamine, its phosphorylated derivatives and folates are illustrated in Figure 3a.

Figure 3. Folate and related transporters and the processes that impact transmembrane folate flows and gradients. (a) Transport mediated by the SLC19 family of solute transporters. Thiamine (T+), a cation, is transported into cells via SLC19A2 and SLC19A3. Within cells, thiamine is metabolised to thiamine pyrophosphate (TPP), an anion, in a reaction mediated by thiamine pyrophosphate kinase (TPK). TPP can be hydrolysed to thiamine monophosphate (TMP), also an anion, mediated by thiamine pyrophosphatase (TPPase). Both are substrates for the reduced folate carrier (RFC; SLC19A1) and are exported by that mechanism. Folates enter cells via RFC and are not substrates for the thiamine transporters. Likewise, thiamine is not a substrate for RFC. (b) Folate transporters. The proton-coupled folate transporter (PCFT) is a folate (Fol)–H+ symporter that functions most efficiently in an acidic extracellular environment. The reduced folate carrier (RFC) is an anion exchanger that utilises the transmembrane organic phosphate (OP) gradient to achieve uphill transport into cells. Folate receptors FRα and FRβ are high-affinity folate-binding proteins that transport folates into cells via an endocytic mechanism. Once in the cytoplasm, the vesicle acidifies, folate is release from the receptor, and is exported from the endosome by a mechanism proposed to be mediated at least in part by PCFT. Folate monoglutamates are exported from cells via the multidrug- resistance-associated proteins (MRPs) and the breast-cancer-resistant protein (BCRP).

Additional evidence for utilisation of RFC by structurally unrelated anions comes from the observation that folate influx is enhanced in RFC-containing membrane vesicles by phosphate or sulfate in the trans compartment (Ref. Reference Yang, Sirotnak and Dembo30). Likewise, depletion of extracellular anions impairs efflux of folates from cells; an activity that is restored when extracellular anions such as thiamine pyrophosphate, AMP or phosphate are added (Ref. Reference Henderson and Zevely20).

Thus, RFC is not influenced by the cellular energy charge, per se. Indeed, inhibition of anaerobic or aerobic metabolism resulting in ATP depletion enhances rather than diminishes the transmembrane folate gradient mediated by RFC (Refs Reference Goldman31, Reference Fry, White and Goldman32, Reference Dembo, Sirotnak and Moccio33). This is probably due to (1) inhibition of ATP-binding-cassette proteins that export folates and oppose the concentrative impact of RFC (Ref. Reference Kruh and Belinsky34), and (2) maintenance of the net transmembrane adenine nucleotide gradient, because ADP and AMP generated from ATP are more potent inhibitors of RFC-mediated folate transport than ATP (Refs Reference Henderson and Zevely20, Reference Goldman21).

RFC is characterised by 12 transmembrane domains (TMDs) and cytoplasmically oriented N- and C-termini (Refs Reference Cao and Matherly35, Reference Ferguson and Flintoff36, Reference Liu and Matherly37) (Fig. 4). Human RFC is N-glycosylated at an N-glycosylation consensus site in the loop connecting TMD1 and TMD2 (Asn58) (Ref. Reference Wong38). A large loop domain that connects TMD6 and TMD7 is poorly conserved between species and can be replaced altogether by a nonhomologous segment from the SLC19A2 carrier (Ref. Reference Liu, Witt and Matherly39). When separate TMD1–TMD6 and TMD7–TMD12 RFC half-molecules are coexpressed in human RFC-null cells, they are targeted to the plasma membrane surface and restore transport activity (Ref. Reference Witt, Stapels and Matherly40). Hence, the role of the TMD6–TMD7 loop domain is primarily to provide appropriate spacing between the TMD1–TMD6 and TMD7–TMD12 segments for optimal transport.

Figure 4. Gene structure and membrane topology of the reduced folate carrier. (a) Schematic of the upstream region of SLC19A1, the human gene encoding the reduced folate carrier (RFC). There are six alternative noncoding regions, each preceded by a separate promoter, spanning ∼35 kb upstream of the major translation start site. The alternative promoters transcribe unique RFC transcripts, each with a distinct 5′ untranslated region (5′UTR) fused to a common coding sequence. Alternative splicing for the A1/A2, A, B and D 5′UTRs has been described. For the A1/A2 and A 5′UTRs, upstream AUG start codons occur in-frame within the RFC noncoding sequence and result in N-terminally modified RFC protein isoforms, with 64 and 22 additional N-terminal amino acids, respectively. (b) Membrane topology of the human RFC including 12 transmembrane domains (TMDs), internally oriented N- and C-termini, the large cytosolic loop between TMD6 and TMD7 and the N-glycosylation site at Asn58.

Studies with RFC mutants implicated conserved amino acids in TMD1, TMD2, TMD3, TMD4, TMD8, TMD10 and TMD11 as important for transport (Ref. Reference Matherly, Hou and Deng4), and recent results with N-hydroxysuccinimide [3H]methotrexate radioaffinity labeling localised binding of the substrate γ-carboxyl group to Lys411 in TMD11 of hRFC (Ref. Reference Deng41). By exhaustive cysteine-scanning mutagenesis and accessibility to membrane-impermeable thiol-reactive agents of a ‘cysteine-less’ human RFC molecule, amino acids localised in TMD4, TMD5, TMD7, TMD8, TMD10 and TMD11 were implicated in forming the putative substrate-binding pocket (Refs Reference Hou42, Reference Hou43). This is consistent with crystal structures for the bacterial MFS proteins, LacY and GlpT (Refs Reference Abramson44, Reference Huang45).

RFC is ubiquitously expressed with patterns of localisation (in intestine, hepatocytes, renal epithelial cells, choroid plexus) that have suggested its integral role in specialised tissues that are important for in vivo folate homeostasis (Refs Reference Whetstine, Flatley and Matherly46, Reference Liu47). Human RFC is intricately regulated by transcriptional controls involving as many as six alternative promoters and noncoding regions that generate up to 15 distinct 5 untranslated regions (UTRs) fused to a common coding sequence (Ref. Reference Matherly, Hou and Deng4) (Fig. 4). The net level of RFC transcripts among different tissues probably results from both ubiquitous (Sp, USF) and tissue-specific (Ap1, C/EBP) transcription factors which, when combined, transactivate or repress transcription in response to tissue-specific stimuli. Other factors that are probably important in the regulation of this gene include promoter methylation, general promoter architecture and chromatin structure (Ref. Reference Matherly, Hou and Deng4).

The diverse human RFC 5′UTRs are subject to post-transcriptional controls, including effects on 5′CAP-dependent translation and transcript stabilities (Ref. Reference Payton48). For many 5′UTRs, the effects on steady-state RFC gene transcripts and proteins are subtle and can be overshadowed by differences in promoter activities. However, for noncoding exons A1/A2, A and D, there were profound decreases in steady-state hRFC compared with other 5′UTRs (Ref. Reference Payton48). For the A1/A2 and A 5′UTRs, upstream AUGs occur in-frame within the SLC19A1 coding sequence and result in N-terminally modified RFC protein isoforms, with 64 and 22 additional N-terminal amino acids, respectively (Refs Reference Payton48, Reference Flatley49). The biological significance of these modified RFC proteins is unclear.

High-frequency polymorphisms have been described in RFC involving both the coding region (G80A) and promoters A1/A2 and A (Refs Reference Flatley49, Reference Chango50, Reference Whetstine51, Reference Whetstine, Witt and Matherly52). G80A RFC is associated with an increased risk of fetal abnormalities (Refs Reference De Marco53, Reference Morin54) and methotrexate toxicity in patients with acute lymphoblastic leukaemia (Ref. Reference Laverdiere55). However, the clinical significance of G80A remains controversial (Refs Reference Matherly, Hou and Deng4, Reference Matherly56). The presence of a 61-bp-repeat polymorphism in the SLC19A1 A promoter may protect against neural tube defects (Ref. Reference O'Leary57).

The proton-coupled folate transporter

The proton-coupled folate transporter (PCFT) is a recently discovered folate carrier (SLC46A1) (Refs Reference Qiu7, Reference Nakai58, Reference Umapathy59). There are two other members of this family (SLC46A2 and SLC46A3) but their functions are not known. The gene that encodes human PCFT (SLC46A1) is located on chromosome 17q11.2. PCFT was initially reported to be a low-affinity haem transporter (influx K m of 125 µM) that is pH independent. It was designated as haem carrier protein-1 (HCP1), which mediates haem-associated iron absorption in the small intestine (Ref. Reference Shayeghi60). However, although haem is a weak inhibitor of folate transport in mammalian cells, a haem current could not be detected in Xenopus oocytes injected with PCFT cRNA and neither haem nor haemin inhibited folate currents in oocytes. (Refs Reference Qiu7, Reference Nakai58, Reference Umapathy59). At this point, the role that PCFT might play in haem transport is unclear. What is clear is that PCFT is a high-affinity folate transporter with a low pH optimum. Its identification now explains the molecular basis for the long-recognised low pH folate transport activities in normal and malignant mammalian cells (Refs Reference Zhao and Goldman8, Reference Henderson and Strauss61, Reference Zhao62, Reference Kuhnel, Chiao and Sirotnak63, Reference Sierra and Goldman64, Reference Assaraf, Babani and Goldman65).

Folate transport mediated by human, mouse and rat PCFTs is electrogenic, indicating that there is a net translocation of positive charges as each folate molecule is transported (Refs Reference Qiu7, Reference Umapathy59, Reference Qiu66, Reference Zhao67). Folate-induced currents in Xenopus oocytes microinjected with PCFT cRNA increase as the pH is decreased in parallel to increased transport of tritiated folates (Refs Reference Qiu7, Reference Qiu66). This is opposite to what is observed for RFC, where transport activity falls with decreasing pH from pH 7.4 and is negligible below a pH of 6.0–6.5 (Refs Reference Sierra68, Reference Wang, Zhao and Goldman69). If folates are bivalent anions, as is assumed to be the case, more than two protons must be co-transported with each folate molecule to account for the positive charge of the PCFT–folate–proton complex. Hence, PCFT functions as a folate–proton symporter: the downhill flow of protons via PCFT is coupled to the uphill flow of folates into cells (Fig. 3b). Early studies with rodent jejunal apical brush-border membrane vesicles provided insight into the energetics of what would later be recognised as PCFT-mediated transport. A transvesicular pH gradient resulted in increased unidirectional folate transport and substantial transmembrane folate concentration gradients, from the low-pH to the high-pH compartment, consistent with a proton-coupled process (Ref. Reference Schron, Washington and Blitzer70).

Although the substrate specificity for PCFT shares some similarity with RFC, there are important differences, including a marked difference in pH optima that impacts affinities for transport substrates. The RFC influx K m values are comparable at pH 7.4 and pH 5.5. The fall in transport with decreasing pH is due instead to a marked decrease in influx V max (Ref. Reference Wang, Zhao and Goldman69). By contrast, for PCFT, the influx K m for folates is increased and V max is decreased, upon an increase in pH from 5.5 to 7.4. However, the pattern and magnitude of these changes varies among different transport substrates (Ref. Reference Qiu7). Most notable is the relatively small change in influx K m and V max for pemetrexed, compared with other folates, with increasing pH. Because of this, PCFT mediates pemetrexed pharmacological effects at physiological pH (Refs Reference Qiu7, Reference Chattopadhyay, Moran and Goldman13, Reference Zhao67). Hence, like the divalent metal-ion transporter DMT1, PCFT mediates transport of folates in the absence of a proton gradient (Ref. Reference Mackenzie71). RFC and PCFT are both stereospecific for 5-formylTHF (Refs Reference Qiu7, Reference Sirotnak72).

The PCFT expression pattern in human tissues provides clues as to its functional roles. In murine and human tissues, there are high levels of SLC46A1 mRNA in small intestine, kidney, liver, placenta, retina and brain. Within the intestine, the highest PCFT levels are found in the proximal jejunum and duodenum (Refs Reference Qiu7, Reference Qiu66, Reference Inoue73).

Information on PCFT secondary structure is emerging. Hydropathy analyses predict a protein with 12 transmembrane domains and N- and C-termini oriented to the cytoplasm (Fig. 5). The latter was confirmed by immunofluorescence studies of haemagglutin-tagged PCFT (Refs Reference Qiu66, Reference Unal74). The loop domain between the first and second transmembrane domains must be extracellular, because the two putative N-glycosylation consensus sites in this region are glycosylated. N-glycosylation does not appear to be required for either PCFT trafficking or function (Ref. Reference Unal74).

Figure 5. Genomic organisation and predicted secondary structure of the proton-coupled folate transporter and mutations in patients with hereditary folate malabsorption. (a) Genomic organisation of SLC46A1, the gene encoding the proton-coupled folate transporter (PCFT); positions of the various mutations, as reported, in the first to fourth exons are indicated. (b) A schematic of a predicted human PCFT topology showing confirmed N-glycosylation sites (N58, N68) between the first and second transmembrane domains with the N- and C- termini oriented to the cytoplasm. The positions of reported mutations in the protein derived from patients with the autosomal recessive disorder hereditary folate malabsorption (HFM) are indicated.

Both RFC (Ref. Reference Liu47) and PCFT (Ref. Reference Qiu66) expression is markedly increased in the small intestine when mice are fed a folate-deficient diet. However, the underlying regulatory mechanisms for these changes await definition.

The impact of pH on the relative contributions of RFC and PCFT to folate transport: focus on intestinal folate absorption

The pH at the transport interface is an important determinant of the relative contributions of RFC and PCFT to overall folate uptake when these transporters are expressed at the same site in the same tissue, as is frequently the case. When the pH is 7.4, PCFT transport function is low to negligible (depending on the folate substrate) and RFC function is maximal. As the pH drops, RFC function decreases and PCFT activity increases. At some point, RFC transport disappears altogether and PCFT becomes the sole transport route (Refs Reference Qiu7, Reference Qiu66, Reference Wang, Zhao and Goldman69). From a physiological perspective, the critical transport interfaces where there is an acid pH include: (1) the microclimate of the duodenum and proximal jejunum apical brush-border membranes, where several Na+/H+ exchangers generate a pH of 5.8–6.0, and where folates are absorbed from the diet (Refs Reference Yun75, Reference McEwan76, Reference Ikuma77, Reference Said, Smith and Redha78); and (2) within acidified endosomes containing folate receptors (pH ∼6.0–6.5) from which, following internalisation from the cell surface, folates are exported into the cytoplasm (Ref. Reference Yang79). It is possible that there are other, as yet unidentified, transport interfaces where ambient pH is low because of localised activity of Na+/H+ exchangers.

RFC and PCFT are expressed at the apical brush-border membrane of the proximal jejunum (Refs Reference Nakai58, Reference Qiu66, Reference Wang80, Reference Subramanian, Marchant and Said81); however, the acidic pH clearly favours PCFT over RFC (Fig. 6). Indeed, there is a large literature that demonstrates a low pH optimum at this site for folate transport and a K m for folic acid at or below 1 µM – properties clearly different from those reported for RFC. These encompass a broad spectrum of systems: intact intestine in man and rodents; isolated intestinal loops, rings and everted sacs in vitro; and isolated intestinal cells, cell lines or membrane vesicles of intestinal origin (Refs Reference Mason, Rosenberg and Johnson82, Reference Selhub and Rosenberg83, Reference Mason84).

Figure 6. Intestinal absorption of dietary folates. Dietary 5-methylTHF polyglutamates (Fol-pg) are hydrolysed to monoglutamate (Fol) by glutamate carboxypeptidase II (GCII) and then transported into cells via the proton-coupled folate transporter (PCFT). Both hydrolysis and PCFT-mediated transport have a low pH optimum and are favoured by the low pH within the microenvironment at the jejunal villi (indicated in blue) that is generated by Na+/H+ exchangers (NHE). RFC is expressed at the apical brush-border membrane but, as indicated by the red cross, is not functional at the pH in this region at usual folate dietary levels. Cellular folates exit the basolateral membrane by a mechanism that probably involves a member of the multidrug-resistance-associated protein (MRP) family of ATP-binding-cassette (ABC) exporters.

However, despite this, because RFC was identified at the intestinal apical brush-border membrane and there was no other known transporter at this location, absorption was attributed to RFC. Indeed, the functional discrepancies between intestinal transport and RFC-mediated transport were attributed to post-translational modifications of RFC that altered its functional properties, although such modifications were never identified (Refs Reference Kumar85, Reference Chiao86). Further evidence that the low-pH folate transport activity is due to a carrier genetically distinct from RFC came from studies in which RFC was deleted from the genome, mutated with loss-of-function, or was silenced. In these studies with a variety of cell lines, including those of intestinal origin, transport at pH 7.4 was lost or markedly diminished but the low-pH transport activity was preserved (Refs Reference Zhao62, Reference Chattopadhyay87, Reference Zhao, Hanscom and Goldman88, Reference Wang89). However, it remains unexplained how in one report siRNA to RFC suppressed folate transport activity in rat-derived intestinal epithelia cells at low, but not physiological pH (Ref. Reference Balamurugan and Said90).

Ultimately, the critical role that PCFT plays in intestinal folate absorption was unequivocally established with the demonstration that subjects with HFM invariably have loss-of-function mutations in the SLC46A1 gene (see below).

The folate receptors

Folate receptors FRα, FRβ and FRγ are very high affinity folate-binding proteins, encoded by three distinct genes located on chromosome 11. Folate receptors are homologous proteins (68–79% identical amino acid sequences), characterised by disparate patterns of tissue expression (see below). FRα and FRβ are both GPI-anchored proteins that mediate folate transport (Refs Reference Kamen and Smith5, Reference Salazar and Ratnam6, Reference Lu and Low91).

Folate receptors have high affinities for folic acid (K d 1–10 nM) (Ref. Reference Jansen and Jackman92). FRα and FRβ from both human and murine sources exhibit different specificities for (6S)- and (6R)-diastereomers of reduced folates, such as 5-methylTHF and 5-formylTHF (Refs Reference Brigle93, Reference Wang94). The markedly lower binding affinities of (6S)-5-methylTHF for FRβ compared with FRα was attributed to Leu49, Phe104 and Gly164 in FRβ, because replacement of these residues with the corresponding residues from FRα (Ala, Val and Glu, respectively) reconstituted the FRα phenotype (Ref. Reference Maziarz95).

Mechanistically, folate internalisation by membrane-associated folate receptors involves receptor-mediated endocytosis (Refs Reference Kamen and Smith5, Reference Salazar and Ratnam6, Reference Lu and Low91, Reference Kamen96, Reference Rothberg97). The process is initiated when a folate molecule binds to a folate receptor on the cell surface. This is followed by invagination of the plasma membrane at that site and the formation of a vesicle (endosome) that migrates along microtubules in the cytoplasm to the perinuclear endosomal compartment where it is acidified to a pH of ∼6.0–6.5. This results in dissociation of the folate from the folate receptor complex (Ref. Reference Yang79). Folate ligand is then exported into the cytoplasm by a process that requires a transendosomal pH gradient (Refs Reference Kamen96, Reference Rothberg97, Reference Kamen, Smith and Anderson98, Reference Prasad99). Recently, PCFT has been proposed as a mechanism of folate export from endosomes (Refs Reference Qiu7, Reference Umapathy59, Reference Andrews100) (Fig. 3, see below).

The physiological roles of folate receptors are unclear in all but a few cases. Although FRα and FRβ can transport folate into cells, this is inefficient compared with transporters such as RFC (Refs Reference Sierra101, Reference Spinella102). FRα is expressed in epithelial cells of the kidney, choroid plexus, retina, uterus and placenta (Refs Reference Salazar and Ratnam6, Reference Parker103). In proximal renal tubule cells, FRα is expressed at the apical (luminal) surface; however, in retinal pigment epithelium, it is expressed on the basolateral membrane (Refs Reference Smith104, Reference Chancy105). FRα is also expressed in tumours, particularly nonmucinous adenocarcinomas of the ovary, uterus and cervix (Ref. Reference Parker103). For ovarian carcinomas, FRα expression correlates with histological grade and stage (Ref. Reference Toffoli106). FRα is negatively regulated by the oestrogen receptor (Ref. Reference Kelley, Rowan and Ratnam107), whereas dexamethasone, a glucocorticoid receptor agonist, is a positive regulator of FRα (Ref. Reference Tran108).

FRβ is expressed during normal myelopoiesis and is present in placenta, spleen, thymus and in CD34+ monocytes (Refs Reference Ratnam109, Reference Wang110, Reference Reddy111, Reference Ross112). A nonfunctional form of FRβ was reported in CD34+ human haematopoietic cells (Ref. Reference Reddy111). FRβ is expressed in chronic myelogenous leukaemia and acute myelogenous leukaemia cells (Refs Reference Wang110, Reference Ross112, Reference Elnakat113). In the latter, FRβ expression is induced by treatment with retinoid-receptor agonists including all-trans retinoic acid (Ref. Reference Wang110). This is independent of cell differentiation or proliferation status and was not observed in nonmyeloid cells.

Folate transport mediated by ATP-binding-cassette transport proteins and other solute carriers

Beyond the transporters that are highly specific for folates, there are other potential folate transport routes. Relevant ATP-binding-cassette exporters include the multidrug-resistance-associated proteins, MRP1-MRP5 (ABCC1-ABCC5) and the breast cancer resistance protein, BCRP (ABCG2) (Refs Reference Kruh and Belinsky34, Reference Assaraf114, Reference Wielinga115). These are low-affinity, high-capacity transporters (K m values ∼0.2–2 mM for folates and antifolates). Members of this family are widely expressed in mammalian cells and suppress the level of free folates or antifolates that accumulate in most cells grown in vitro (Ref. Reference Kruh and Belinsky34). Some of the shorter-chain-length polyglutamate folates may be weak substrates for MRPs. However, in general, folate polyglutamates are retained within cells (Refs Reference Zhao and Goldman12, Reference Kruh and Belinsky34, Reference Fry, Yalowich and Goldman116).

From a physiological perspective, MRP2 plays a critical role in the export of folates across the bile canalicular membrane, as demonstrated by impaired biliary secretion of methotrexate in MRP2−/− mice (Ref. Reference Masuda117). The role that MRP family members play in the vectorial transport of folates in other tissues is less clear. Of particular interest is their potential role in the export of folates from jejunal enterocytes. MRP2 is expressed at the apical membrane, which would oppose absorption mediated by PCFT (Ref. Reference Mottino118). Since MRP3 is expressed at the basolateral membrane of rat jejunum (Ref. Reference Rost119), it could contribute to folate transport across the jejunal enterocyte by mediating export across the basolateral membrane. MRP1–MRP4 and BCRP are expressed in human jejunum, although relative levels have not been firmly established (Refs Reference Taipalensuu120, Reference Seithel121). Although MRP1 and MRP4 were localised to the basolateral membrane of some tissues, their localisation in human jejunum is not known (Ref. Reference Kruh and Belinsky34).

The SLC21 family of facilitative carriers transport organic anions, whereas the SLC22 family transport both organic anions and cations (Refs Reference Koepsell and Endou122, Reference Sekine, Miyazaki and Endou123, Reference Hagenbuch and Meier124). Both are expressed in tissues that mediate vectorial transport – the intestine, kidney and liver. Some of these carriers transport folates and antifolates. Of the SLC21 members, OAT-K1 and OAT-K2 are kidney specific and are expressed at the apical brush-border membrane. These transporters have K m values for methotrexate and 5-methylTHF of ∼2 µM and could play a role in reabsorption of folates at the proximal tubule (Ref. Reference Masuda125). OAT1, OAT2 and OAT3 belong to the SLC22 family and are expressed at the basolateral membrane of renal tubules (Ref. Reference Rizwan and Burckhardt126). These transporters generally have low affinities for methotrexate (10–700 µM), depending on the expression system (Refs Reference Uwai127, Reference Takeda128, Reference Nozaki129, Reference Cha130, Reference VanWert and Sweet131). Since RFC is also present at the basolateral membrane, it is unlikely that the SLC22 transporters have a major role in renal reabsorption of folates.

Genetic deletion of the reduced folate carrier and folate receptors

Genetic deletion of Slc19a1 and folate receptors has been achieved in the mouse. RFC heterozygous (+/–) mice have no phenotype. Loss of both alleles (−/−) is embryonic lethal; however, mice can be brought to term when pregnant females receive subcutaneously injected folic acid. However, pups die within ∼12 days of birth due to failure of erythropoiesis in bone marrow, liver and spleen (Ref. Reference Zhao132). More recent studies on Slc19a1 −/− mice from pregnant females supplemented with low levels of folate reveal a variety of congenital malformations (Ref. Reference Gelineau-van Waes133). FRβ-null mice are normal, as are mice heterozygous for FRα. Loss of both alleles encoding FRα protein is embryonic lethal; the embryos are arrested at the time of neural tube closure (Ref. Reference Piedrahita134). If, however, pregnant females receive parenteral 5-formylTHF throughout gestation, the pups are normal and can be maintained without any apparent abnormalities through to adulthood on a standard chow (R. Finnell, The Texas Institute for Genomic Medicine, Houston, TX, pers. commun.).

Hereditary folate malabsorption

The human PCFT-null genotype/phenotype is known within the context of the rare autosomal recessive disorder HFM (Refs Reference Qiu7, Reference Zhao9, Reference Min10, Reference Geller135). The major defects in HFM are: (1) impaired intestinal folate absorption, resulting in severe systemic folate deficiency; and (2) impaired transport of folates into the central nervous system, associated with very low to undetectable levels of folate in the cerebrospinal fluid (CSF).

PCFT+/− individuals are completely normal. Infants with HFM are normal at birth. Neural tube defects are not seen, indicating that there is adequate placental delivery of folates from mother to fetus. Signs of HFM begin several months after birth, presumably when folate stores provided by the mother during gestation are depleted. The infants develop anaemia, sometimes pancytopaenia, reflecting folate deficiency in rapidly proliferating haematopoietic cells. Gastrointestinal involvement manifests as severe diarrhoea. Immune deficiency due to hypoimmunoglobulinemia is frequent, resulting in infections usually associated with immunocompromised states (Pneumocystis carinii and cytomegalovirus pneumonia). Patients frequently have neurological signs including seizures, neurodevelopmental defects and/or mental retardation. Systemic signs of the disease can be obviated or reversed by low-dose parenteral folate or higher-dose oral folate, which normalises blood folate levels. However, very high blood folate levels are required to achieve CSF folate levels in the normal range (Ref. Reference Geller135).

Eight families with HFM have been reported to date with loss-of-function mutations in SLC46A1, the gene encoding PCFT. The mutations are indicated in Figure 5 (Refs Reference Qiu7, Reference Zhao9, Reference Min10, Reference Lasry136). No mutations were detected in the genes encoding RFC or FRα in patients with HFM. These observations unequivocally establish PCFT as the mechanism by which folates are absorbed across the apical brush-border membrane of the proximal jejunum under normal conditions. This is consistent with the low pH (5.8–6.0) at the jejunal brush-border membrane and observations that: (1) when jejunal pH is decreased, as occurs with pancreatic insufficiency, folate absorption is increased (Ref. Reference Russell137); and (2) when the pH is increased, as occurs with ingestion of antacids or after gastrectomy, intestinal folate absorption is decreased (Ref. Reference Russell138).

The clinical observation that high doses of oral folates can restore systemic folate levels in individuals with HFM raises the question of how intestinal folate is absorbed under these conditions (Ref. Reference Geller135). Defects due to SLC46A1 mutations that decrease the affinity for folates could be overcome by high doses of oral folates. However, in several cases, mutations produce a stop codon, a frameshift in exon 1, or a splicing defect, resulting in the absence of PCFT protein. In other cases, point mutations resulted in defects in trafficking, stability and/or a complete loss of intrinsic function (Refs Reference Qiu7, Reference Zhao9, Reference Min10, Reference Lasry136). Since passive diffusion of folates is assumed to be negligible even in the presence of pharmacological doses of folates, it is likely that intestinal absorption is mediated by RFC, albeit inefficiently, under these conditions.

The folate one-carbon journey from food to macromolecules

This section traces the pathway of folates ingested and the various folate transporters that mediate folate transport across epithelia and into systemic tissues.

Hydrolysis of folate polyglutamates

The major natural folate forms in the diet are polyglutamate congeners of 5-methylTHF that are not substrates for the absorptive process (Refs Reference Rosenberg139, Reference Butterworth, Baugh and Krumdieck140). This is consistent with the recent demonstration that affinities of PCFT for the di- to penta-glutamates of methotrexate are very low (Ref. Reference Qiu66). Rather, folate polyglutamate derivatives must be hydrolysed to their monoglutamate forms by glutamate carboxypeptidase II in human intestine and γ-glutamyl hydrolase in rat intestine (Refs Reference Halsted141, Reference Shafizadeh and Halsted142). The γ-glutamate hydrolytic reaction has a low pH optimum similar to the absorptive process, consistent with the low pH at the surface of mucosal cells in the proximal jejunum (Fig. 6).

Intestinal absorption

Once folate monoglutamate is generated, it is transported across the apical brush-border membrane of the proximal jejunum mediated by PCFT. Because PCFT transport is concentrative, driven by the transmembrane proton gradient generated by Na+/H+ exchangers, the high folate levels in enterocytes should facilitate folate efflux across the basolateral membrane into the periserosal space, and from there, folates enter the vascular system. The mechanism of export from enterocytes is not clear; neither RFC nor PCFT is expressed at the basolateral membrane. However, MRPs are expressed at this site, particularly MRP3 (Ref. Reference Kruh and Belinsky34), and might represent the route of export of folates (Fig. 6).

Transport to, and disposition in, the liver

After intestinal absorption, folates enter the hepatic portal system and are delivered to the hepatic sinusoids in apposition to the hepatocyte basolateral (sinusoidal) membrane. PCFT is highly expressed in the liver, and our preliminary results suggest that it localises to the sinusoidal membrane. This is consistent with a dominant low-pH folate transport activity in hepatocytes and in sinusoidal membrane vesicles derived from hepatocytes (Refs Reference Horne and Reed143, Reference Horne144). In the latter, concentrative folate transport is produced with a transvesicular pH gradient. There is minimal transport activity at pH 7.4, consistent with a low level of RFC activity (Refs Reference Horne, Reed and Said145, Reference Horne146), although RFC is detected at the hepatocyte membrane (Ref. Reference Wang80). It is unclear what the pH is within hepatic sinusoids where hepatic portal vein blood, derived from the intestine, pancreas and spleen, mixes with hepatic artery blood. It has been proposed that a Na+/H+ antiporter at the sinusoidal membrane may generate a local extracellular region of high acidity (Ref. Reference Arias and Forgac147), as is the case in the proximal jejunum.

Folates that enter the liver have three potential destinations. (1) Folates can be converted to polyglutamate storage forms or (2) they can be secreted into the bile at the hepatic canalicular membrane, mediated by MRP2 (Ref. Reference Masuda117), whereby they return to the duodenum and jejunum and are subsequently reabsorbed, thus completing the cycle of enterohepatic circulation. (3) Folate monoglutamates, formed by hydrolysis of polyglutamate forms stored in hepatocytes, or delivered directly from the hepatic portal vein, can enter the hepatic vein, ultimately reaching the systemic circulation whereby they accumulate in, and meet the one-carbon requirements of, peripheral tissues. Folates in blood also encounter epithelial barriers separating compartments containing highly folate-dependent tissues. Notable examples are neural tissues isolated by the vascular blood–brain barrier and the blood–choroid-plexus–CSF barrier.

Transport into systemic tissues

Membrane transport of folates into systemic tissues via the arterial system where the pH is 7.4 is mediated by the RFC. Although PCFT is often coexpressed with RFC, PCFT function would be minimal and would probably not contribute to the delivery of folates systemically, unless, as suggested above, there are tissues where Na+/H+ exchangers produce acid microenvironments at transport interfaces. PCFT may also have a role in FR-mediated transport (see below).

Filtration and reabsorption in the kidney

Blood folates not bound to serum proteins are filtered at the glomerulus; however, because of a highly efficient reabsorptive mechanism, little or none is lost in the urine at physiological levels of folate intake (Ref. Reference Goresky, Watanabe and Johns148). The initial step in reabsorption involves tight binding to FRα that is highly expressed at the luminal brush-border membrane of proximal tubules. The affinities of folates for this site are consistent with their affinities for FRα (Refs Reference Selhub, Nakamura and Carone149, Reference Selhub and Rosenberg150) and the urinary clearance of folates is inversely proportional to their affinities for FRα (Ref. Reference Selhub151). In the FRα−/− mouse (maintained on standard chow – see above) there is increased folic acid clearance and decreased 5-methylTHF uptake (Ref. Reference Birn152). Folates accumulate to high levels in the kidney, reflecting the large component bound to FRα. This is followed by internalisation of receptors, release of folate into the cytoplasm and export at the basolateral membrane by RFC, where the pH is optimal for carrier function (Refs Reference Wang80, Reference Goresky, Watanabe and Johns148, Reference Selhub, Nakamura and Carone149). Several SLC21 solute carriers are expressed at the apical brush-border membrane of proximal renal tubule cells and probably contribute to renal folate absorption, particularly at high folate loads, when FRα-mediated absorption is saturated (Ref. Reference Birn152). The role of PCFT in renal folate reabsorption is not clear. mRNA encoding PCFT protein is highly expressed in the kidney, but its exact location has not been defined (Refs Reference Qiu7, Reference Qiu66). In renal brush-border membrane vesicles, the folate flux and net transport is optimal at low pH when the pH of the trans compartment is 7.4, consistent with a PCFT-mediated process (Refs Reference Bhandari, Joshi and McMartin153, Reference Bhandari, Fortney and McMartin154). The pH in the proximal tubule starts at 7.4 and falls to ~6.8 as filtrate passes down the tubule, where bicarbonate is reabsorbed and chloride is secreted (Ref. Reference Jaramillo-Juarez, Aires and Malnic155). Under these conditions, should PCFT be present, only modest PCFT-mediated transport at the brush-border membrane would be expected.

Although a rigorous analysis of renal folate clearance in subjects with HFM has not been reported, some information can be gleaned from published studies. In one patient with HFM, the clearance of folate from blood, after an intravenous bolus, was no different from that of a normal subject over the first 2–3 hours (Ref. Reference Santiago-Borrero156). In another case, clearance in a patient with HFM over this interval was similar to that published earlier for normal subjects (Refs Reference Goresky, Watanabe and Johns148, Reference Lanzkowsky, Erlandson and Bezan157). These observations suggest that PCFT is not required for reabsorption of folates in the proximal tubule. However, since the initial phase of folate clearance from blood is influenced by uptake and retention in systemic tissues and tight binding of filtered folate to FRα, more than a few hours may be necessary to fully decipher the role of PCFT in the reabsorptive process. It is also possible that at least a component of the folate-receptor-mediated folate reabsorption in the proximal tubule represents a transcytosis in which vesicles formed at the brush-border membrane retain folate as they transit intact to the basolateral membrane where their contents are discharged to the peritubular space. However, uptake of tritiated folate alone, or folate coupled to colloidal gold particles, into renal tubular epithelial cells is consistent with translocation of vesicles across the brush-border membrane, followed at least in part by recycling back to that membrane via dense apical tubules (Refs Reference Birn, Nielsen and Christensen158, Reference Birn, Selhub and Christensen159).

Transport of folates across the blood–brain barrier and the choroid-plexus–CSF barrier

There are two potential routes of delivery of substrates to the brain, the blood–brain barrier at the cerebral vascular endothelium, and the blood–CSF barrier at the choroid plexus. RFC is localized to the vascular blood–brain barrier (Ref. Reference Wang80) and we have found that PCFT protein is expressed there as well. mRNA encoding FRα is neither expressed in brain parenchyma nor is FRα protein detected at the blood–brain barrier (Refs Reference Weitman, Frazier and Kamen160, Reference Kennedy161). The high rate of delivery of 5-methylTHF to brain parenchyma is consistent with folate extraction from blood mediated predominantly at the vascular blood–brain barrier (Ref. Reference Wu and Pardridge162). Transport of 5-methylTHF into human brain capillaries is saturable and can be inhibited by low levels of 5-methylTHF or folic acid (Ref. Reference Wu and Pardridge162). Although this has been interpreted as implicating a role for FRα, this is also consistent with a PCFT-mediated process for which folic acid and 5-methylTHF have comparable high affinities. However, there is no evidence that the pH at this transport interface is acidic.

The choroid plexus represents the pathway for the active transport of substrates and metabolites into and out of the CSF (Ref. Reference Segal163). The concentration of most small molecules in CSF is less than in blood (Ref. Reference Segal163). The opposite is the case for folates. The usual CSF:blood folate ratio is 2–3:1 (Ref. Reference Geller135), consistent with concentrative folate transport across the choroid plexus. It is clear that PCFT is required to achieve usual blood:CSF folate gradients, because this ratio is reversed in subjects with HFM (Ref. Reference Geller135). Evidence suggesting that FRα plays a role in this process comes from the observations that: (1) this protein is highly expressed in choroid plexus; and (2) blocking autoantibodies to folate receptors have been found in the blood of patients with cerebral folate deficiency. In this disorder, there are low levels of CSF folate even though folate intestinal absorption and folate blood levels are normal (Refs Reference Moretti164, Reference Moretti165, Reference Ramaekers166, Reference Schwartz167, Reference Ramaekers168). These subjects do not have mutations in genes encoding FRα, RFC or PCFT (Ref. Reference Moretti164).

Studies on transport of folates into the choroid plexus in vivo and in vitro further substantiate a role for this organ in the transport of folates (Refs Reference Kennedy161, Reference Wu and Pardridge162, Reference Spector and Lorenzo169, Reference Spector and Lorenzo170). We have found that PCFT protein is expressed at the basolateral membrane of ependymal cells at the capillary interface (Ref. Reference Zhao216); RFC is expressed at the apical membrane at the CSF interface (Ref. Reference Wang80). mRNA encoding the FRα protein is expressed in the choroid plexus and is visualised at the basolateral and, to a greater extent, apical basolateral membranes (Refs Reference Kennedy161, Reference Weitman171, Reference Weitman172, Reference Selhub and Franklin173, Reference Patrick174). Although both interfaces are likely at neutral pH, Na+/H+ antiporters expressed at the basolateral membrane (Ref. Reference Segal175) could produce an acid microclimate that facilitates PCFT function, as occurs in the proximal small intestine. One possible model that includes FRα and PCFT envisions FRα-mediated endocytosis across the basolateral membrane, generating a folate gradient across ependymal cells, followed by the downhill flow of folate across the apical membrane into the CSF mediated by RFC. Although RFC produces small folate gradients directed into cells, it mediates very rapid bidirectional fluxes of folates (Ref. Reference Zhao176). According to this model, PCFT facilitates FRα-mediated endocytosis by serving as a route for folate export from acidified endosomes into the cytoplasm (Fig. 3). There is evidence that PCFT augments FRα-mediated endocytosis in HeLa cells (Ref. Reference Zhao216). Similarly to transport across the vascular blood–brain barrier, 5-methylTHF appears to be the preferred substrate for transport across the choroid plexus (Refs Reference Wu and Pardridge162, Reference Spector and Lorenzo170, Reference Levitt177).

Transport of folates across the placenta

FRβ, RFC and PCFT are all expressed in the placenta (Refs Reference Qiu7, Reference Whetstine, Flatley and Matherly46, Reference Ratnam109, Reference Weitman172, Reference Maddox178), although the location and the spatial relationship among all these transporters has not been established. However, the observation that low levels of folic acid, but not methotrexate, inhibit maternal to fetal [3H]folic acid transport across guinea pig placenta suggests that FRα plays an important role in the initial phase of folate transport from maternal blood at the apical membrane of the syncytiotrophoblast (Refs Reference Sweiry and Yudilevich179, Reference Sweiry and Yudilevich180). Further evidence of a role for FRα in placental transport involves the inhibitory effects of bafilomycin A, which blocks the V-type proton pump, or FCCP, which abolishes the transmembrane proton gradient, on folic acid transport into tumour cells of trophoblastic origin. This is presumably due to their inhibitory effects on folate export from endosomes in the endocytic pathway (Ref. Reference Prasad99). Transport of folic acid in the BeWo trophoblastic cell line is maximal at pH 5.0, reflecting PCFT-mediated transport, and decreases as pH is increased, although a second peak of activity at pH 7.4 is also detected, probably reflecting RFC-mediated transport (Ref. Reference Keating181). Vectorial transport of folic acid across BeWo cells, from the apical compartment (maternal side) at pH 5.5, separated by a semipermeable membrane from the basal compartment (fetal side) at pH 7.4, was far greater than transport from the basal to apical compartments when the pH gradient was reversed (Ref. Reference Takahashi182). This suggests a higher level of PCFT activity at the apical interface than that at the basal interface.

Because the placenta is fetal in origin, and because PCFT–/– subjects with HFM do not have developmental defects associated with folate deficiency, PCFT does not appear to be necessary for placental transport of folate from mother to embryo or fetus, despite its high level of placental expression and its potential role in FRα-mediated endocytosis. The histories of families with HFM reveal that PCFT+/– females can support a normal pregnancy. Unanswered as yet, is whether the loss of two SLC46A1 alleles will affect delivery of folates to the fetus. The oldest reported female with HFM is now aged 28 and has had normal menarche but has not, as yet, become pregnant (Refs Reference Min10, Reference Poncz183, Reference Poncz and Cohen184).

Clinical implications/applications

Folate transport is a critical determinant of folate sufficiency and the integrity of one-carbon metabolism in man. Hence, expression of folate transporters, as determined by genetic, epigenetic and other regulatory factors, is of considerable importance. The requirements for RFC and FRα in embryonic development, and PCFT in infancy, are clear. Folate deficiency during adult life may be associated with transport variations that contribute to other pathophysiologic states including cancer, cardiovascular disease and neurological disorders (Refs Reference Davey and Ebrahim186, Reference Mischoulon and Raab187, Reference Ulrich and Potter188, Reference Martínez, Marshall and Giovannucci189). Folate deficiency in pregnant women is a major factor in fetal abnormalities (Ref. Reference Eichholzer, Tonz and Zimmermann190). Mild transport variations could be compounded by alterations in activities of folate-dependent interconverting and biosynthetic enzymes for which there are known allelic variations (e.g. C677T in MTHFR), which have an impact on cellular distributions of individual THF cofactor forms (Ref. Reference Lucock191). The cumulative effects could be impaired nucleotide biosynthesis, impaired repair of DNA damage, DNA hypomethylation resulting in aberrant oncogene expression, or DNA hypermethylation resulting in silencing of protective genes such as tumour suppressors (Ref. Reference Kim185).

An understanding of the molecular basis for HFM now makes possible a definitive diagnosis of this disorder in families. This allows genetic counselling, along with prenatal and in vitro testing. Individualisation of treatment with specific folates might be possible, based upon the functional characteristics and specificity of individual mutant PCFTs in patients with HFM.

RFC-mediated transport is an important determinant of the antitumour activities of antifolate chemotherapeutic drugs such as methotrexate (Refs Reference Matherly, Hou and Deng4, Reference Zhao and Goldman12, Reference Chattopadhyay, Moran and Goldman13). It was recognised early on that intrinsic and acquired resistance to methotrexate is frequently due to impaired transport in cell lines (Refs Reference Kessel, Hall and Roberts192, Reference Hakala193, Reference Fischer194) and is a factor in resistance to methotrexate in acute lymphoblastic leukaemia and osteogenic sarcoma (Refs Reference Ge195, Reference Guo196, Reference Levy197). Enhanced accumulation of methotrexate and its polyglutamates accompany increased levels of hRFC transcripts and copies of chromosome 21 in hyperdiploid B-precursor acute lymphoblastic leukaemia (Ref. Reference Zhang198).

Recently, pemetrexed was approved for the treatment of cancer in the USA, more than 50 years after the introduction of methotrexate (Ref. Reference Chattopadhyay, Moran and Goldman13). Pemetrexed has an affinity for RFC comparable with that of methotrexate. However, pemetrexed differs from methotrexate in its affinity for PCFT, which is sufficiently high, even at physiological pH, that its activity is preserved in tumour cells that are methotrexate resistant because of loss of RFC function (Refs Reference Chattopadhyay, Moran and Goldman13, Reference Chattopadhyay87, Reference Zhao199).

Research in progress and outstanding research questions

The transcriptional and post-transcriptional controls that contribute to tissue-specific expression of RFC have been largely defined (Ref. Reference Matherly, Hou and Deng4). Although there have been extensive studies of high-frequency sequence polymorphisms in RFC coding and noncoding regions in relation to a variety of pathological states (Refs Reference Matherly, Hou and Deng4, Reference Matherly56), these associations remain controversial. The recent production of a ‘humanised’ RFC mouse in which the mouse Slc19a1 is functionally replaced by the human SLC19A1 gene locus (Ref. Reference Patterson200) holds promise for extending in vitro findings of human RFC regulation and function including polymorphic SLC19A1 gene variants to a clinically relevant in vivo model. This will allow correlations with dietary folate status and biological manifestations of folate deficiency.

Structure–function studies of human RFC have provided substantive insight into its membrane topology, N-glycosylation, important domains and amino acids and three-dimensional helix-packing associations (Ref. Reference Matherly, Hou and Deng4). Preliminary studies indicate that there are higher-order oligomers (e.g. dimers) of RFC (Ref. Reference Hou and Matherly217), as has been observed for other transporters (Ref. Reference Veenhoff, Heuberger and Poolman201). Clarification of RFC oligomeric character is especially important for understanding carrier structure and function, including the mechanism of concentrative folate transport. The existence of homo-oligomeric human RFC might also have an important role in antifolate resistance through potential dominant-negative interactions between mutant and wild-type human RFCs that result in alterations in function and/or trafficking defects.

Since PCFT was only recently discovered, there is only scant information on the structural properties of this transporter. A predicted secondary structure was described and localisation of the N- and C-termini and the first extracellular loop was verified (Refs Reference Qiu66, Reference Unal74). Studies are ongoing to identify key amino acid residues that determine substrate binding, proton coupling and carrier mobility. Future studies will emphasise helix packing and tertiary structure using approaches such as substituted cysteine accessibility mutagenesis methods (Refs Reference Cao and Matherly35, Reference Karlin and Akabas202). The finding of higher-order RFC oligomers raises the intriguing possibility that this might occur for PCFT as well. Studies of PCFT structure and function would be enhanced considerably by the availability of a three-dimensional structural model of this transporter. The extrapolation of a prokaryotic model, based upon the glycerol-3-phosphate transporter crystal structure, to PCFT is appealing (Ref. Reference Lasry136), and this approach has been applied to other eukaryotic solute carriers (Ref. Reference Lemieux203). However, the utility of this and/or other models for the characterization of PCFT will require rigorous experimental verification, as noted above for RFC.

Since folate deficiency is associated with increased risk of colorectal cancer, deciphering the roles of RFC and PCFT in the delivery of folates to the large intestine and their regulation at this site, within the context of dietary and environmental factors, will be of considerable importance. These studies need to take into consideration the recent paradigm that folate deficiency results in an increased frequency of oncogenesis but, once cancers are formed, excess folates may accelerate tumour growth. This has been demonstrated in animal models (Refs Reference Song204, Reference Song205) and there is concern that there may be a similar risk for humans on dietary folate supplements (Refs Reference Ulrich and Potter188, Reference Kim206). For RFC, causal associations with loss of carrier function and colorectal cancer were described in mouse models (Refs Reference Ma207, Reference Lawrance208).

The hypothesis that PCFT is required for folate receptor function, by serving as a route of export from acidified endosomes, broadens the potential biological importance of this carrier. Clarification of this issue could establish a critical role for PCFT in the transport of folates across the blood–choroid-plexus–CSF barrier and explain why transport into the CSF compartment is impaired in HFM. Additional information is also required to clarify the functional role of PCFT in other tissues in which it is highly expressed, particularly where there is no evidence for a substantial acidic milieu at the transport interface. This relates in particular, to the extent to which PCFT mediates folate transport from the hepatic portal vein across the sinusoidal membrane to hepatic cells, reabsorption in the proximal renal tubule, transport across the placenta to the fetus, and transport across the choroid plexus and into brain parenchyma at the blood–brain barrier. These questions will be best addressed by studies on a PCFT-null mouse.

The role that PCFT plays in antifolate delivery to tumour cells requires further exploration. PCFT has a high affinity for pemetrexed and, when transfected into tumour cells, selectivity augments the growth-inhibitory activity of the drug without a salutary effect on other antifolates, such as methotrexate, PT523 or raltitrexed, which have a much lower affinity for PCFT at physiological pH (Ref. Reference Zhao67). It will be important to determine whether PCFT contributes more to the activity of pemetrexed, or to the activities of other antifolates when transport occurs within solid tumours in vivo, where cells are hypoxic, the microenvironment is acidic and PCFT would be expected to operate more efficiently (Refs Reference Helmlinger209, Reference Tredan210, Reference Raghunand211). Likewise, because of the high K m values for antifolate transport at physiological pH, it will be important to determine the role PCFT might play in the delivery of antifolates at the high blood levels achieved in clinical regimens under conditions in which RFC is saturated.

Finally, there is an ongoing interest in the development of new-generation antifolates. Antifolate thymidylate synthase inhibitors were designed with very low affinity for RFC but very high affinity for FRα to minimise toxicity due to uptake via RFC, which is ubiquitously expressed, and to maximise uptake via folate receptors that are more selectively expressed in certain tumours (Refs Reference Theti212, Reference Henderson213, Reference Gibbs214). An analogous strategy was recently described for a series of highly potent FR-targeted antifolate GAR (β-ribosylglycinamideribonucleotide) transformylase inhibitors (Ref. Reference Deng215). It will be of particular interest to determine whether the activities of some of these novel FR-targeted agents will be related to their affinities for PCFT, which might enhance their uptake in the acidic milieu of solid tumors and/or their export from endosomes during the endocytic cycle.

Acknowledgements

The authors wish to thank the reviewers of this manuscript for their very helpful suggestions. This work was supported by grants CA53535 (L.H.M.) and CA82621 (I.D.G.) from the National Institutes of Health.

References

References

1Stokstad, E.L.R. (1990) Historical perspective on key advances in the biochemistry and physiology of folates. In Folic Acid Metabolism in Health and Disease. (Picciano, M.F and Stokstad, E.L.R. eds.), pp. 1-21, Wiley-LissGoogle Scholar
2Jacques, P.F. et al. (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. New England Journal of Medicine 340, 1449-1454CrossRefGoogle ScholarPubMed
3Matherly, L.H. and Goldman, I.D. (2003) Membrane transport of folates. Vitamins and Hormones 66, 403-456CrossRefGoogle ScholarPubMed
4Matherly, L.H., Hou, Z. and Deng, Y. (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer and Metastasis Reviews 26, 111-128CrossRefGoogle Scholar
5Kamen, B.A. and Smith, A.K. (2004) A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Advanced Drug Delivery Reviews 56, 1085-1097Google Scholar
6Salazar, M.D. and Ratnam, M. (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer and Metastasis Reviews 26, 141-152CrossRefGoogle ScholarPubMed
7Qiu, A. et al. (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127, 917-928CrossRefGoogle ScholarPubMed
8Zhao, R. and Goldman, I.D. (2007) The molecular identity and characterization of a Proton-coupled Folate Transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer and Metastasis Reviews 26, 129-139CrossRefGoogle ScholarPubMed
9Zhao, R. et al. (2007) The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 110, 1147-1152CrossRefGoogle ScholarPubMed
10Min, S.H. et al. (2008) The clinical course and genetic defect in the PCFT in a 27-year-old woman with Hereditary folate malabsorption. Journal of Pediatrics 153, 435-437CrossRefGoogle Scholar
11Wessels, J.A., Huizinga, T.W. and Guchelaar, H.J. (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47, 249-255Google Scholar
12Zhao, R. and Goldman, I.D. (2003) Resistance to antifolates. Oncogene 22, 7431-7457CrossRefGoogle ScholarPubMed
13Chattopadhyay, S., Moran, R.G. and Goldman, I.D. (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms and clinical applications. Molecular Cancer Therapeutics 6, 404-417Google Scholar
14Shane, B. (1989) Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitamins and Hormones 45, 263-335CrossRefGoogle ScholarPubMed
15Matherly, L.H. et al. (1987) The effects of 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. Journal of Biological Chemistry 262, 710-717Google Scholar
16Seither, R.L. et al. (1989) Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Journal of Biological Chemistry 264, 17016-17023CrossRefGoogle ScholarPubMed
17Goldman, I.D., Lichtenstein, N.S. and Oliverio, V.T. (1968) Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. Journal of Biological Chemistry 243, 5007-5017Google Scholar
18Goldman, I.D. and Matherly, L.H. (1985) The cellular pharmacology of methotrexate. Pharmacology and Therapeutics 28, 77-102Google Scholar
19Sirotnak, F.M. and Tolner, B. (1999) Carrier-mediated membrane transport of folates in mammalian cells. Annual Review of Nutrition 19, 91-122Google Scholar
20Henderson, G.B. and Zevely, E.M. (1983) Structural requirements for anion substrates of the methotrexate transport system of L1210 cells. Archives of Biochemistry and Biophysics 221, 438-446CrossRefGoogle ScholarPubMed
21Goldman, I.D. (1971) The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Annals of the New York Academy of Sciences 186, 400-422CrossRefGoogle ScholarPubMed
22Labay, V. et al. (1999) Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nature Genetics 22, 300-304Google Scholar
23Fleming, J.C. et al. (1999) The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nature Genetics 22, 305-308Google Scholar
24Diaz, G.A. et al. (1999) Mutations in a new gene encoding a thiamine transporter cause thiamine- responsive megaloblastic anaemia syndrome. Nature Genetics 22, 309-312CrossRefGoogle Scholar
25Dutta, B. et al. (1999) Cloning of the human thiamine transporter, a member of the folate transporter family. Journal of Biological Chemistry 274, 31925-31929CrossRefGoogle ScholarPubMed
26Rajgopal, A. et al. (2001) SLC19A3 encodes a second thiamine transporter, ThTr2. Biochimica et Biophysica Acta 1537, 175-178Google Scholar
27Rindi, G. and Laforenza, U. (2000) Thiamine intestinal transport and related issues: recent aspects. Proceedings of the Society for Experimental Biology and Medicine 224, 246-255CrossRefGoogle ScholarPubMed
28Zhao, R. et al. (2000) Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. Journal of Biological Chemistry 276, 1114-1118CrossRefGoogle Scholar
29Zhao, R., Gao, F. and Goldman, I.D. (2002) Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. American Journal of Physiology Cell Physiology 282, C1512-C1517Google Scholar
30Yang, C.-H., Sirotnak, F.M. and Dembo, M. (1984) Interaction between anions and the reduced folate/methotrexate transport system in L1210 cell plasma membrane vesicles: directional symmetry and anion specificity for differential mobility of loaded and unloaded carrier. Journal of Membrane Biology 79, 285-292Google Scholar
31Goldman, I.D. (1969) Transport energetics of the folic acid analogue, methotrexate, in L1210 cells: Enhanced accumulation by metabolic inhibitors. Journal of Biological Chemistry 244, 3779-3785Google Scholar
32Fry, D.W., White, J.C. and Goldman, I.D. (1980) Effects of 2,4-dinitrophenol and other metabolic inhibitors on the bidirectional carrier fluxes, net transport, and intracellular binding of methotrexate in Ehrlich ascites tumor cells. Cancer Research 40, 3669-3673Google Scholar
33Dembo, M., Sirotnak, F.M. and Moccio, D.M. (1984) Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: further evidence for separate influx and efflux systems with different energetic requirements. Journal of Membrane Biology 78, 9-17CrossRefGoogle ScholarPubMed
34Kruh, G.D. and Belinsky, M.G. (2003) The MRP family of drug efflux pumps. Oncogene 22, 7537-7552Google Scholar
35Cao, W. and Matherly, L.H. (2004) Analysis of the membrane topology for transmembrane domains 7–12 of the human reduced folate carrier by scanning cysteine accessibility methods. Biochemical Journal 378, 201-206Google Scholar
36Ferguson, P.L. and Flintoff, W.F. (1999) Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. Journal of Biological Chemistry 274, 16269-16278CrossRefGoogle ScholarPubMed
37Liu, X. and Matherly, L. (2002) Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochimica et Biophysica Acta 1564, 333-342CrossRefGoogle ScholarPubMed
38Wong, S.C. et al. (1998) Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier. Biochimica et Biophysica Acta 1375, 6-12Google Scholar
39Liu, X.Y., Witt, T.L. and Matherly, L.H. (2003) Restoration of high level transport activity by human reduced folate carrier/ThT1 chimeric transporters: Role of the transmembrane domain 6/7 linker region in reduced folate carrier function. Biochemical Journal 369, 31-37CrossRefGoogle Scholar
40Witt, T.L., Stapels, S.E. and Matherly, L.H. (2004) Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7–12. Journal of Biological Chemistry 279, 46755-46763CrossRefGoogle ScholarPubMed
41Deng, Y. et al. (2008) Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition. Molecular Pharmacology 73, 1274-1281Google Scholar
42Hou, Z. et al. (2006) Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates. Journal of Biological Chemistry 281, 33588-33596CrossRefGoogle ScholarPubMed
43Hou, Z. et al. (2005) Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods. Journal of Biological Chemistry 280, 36206-36213Google Scholar
44Abramson, J. et al. (2003) Structure and mechanism of the lactose permease of Escherichia coli. Science 301, 610-615Google Scholar
45Huang, Y. et al. (2003) Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301, 616-620CrossRefGoogle ScholarPubMed
46Whetstine, J.R., Flatley, R.M. and Matherly, L.H. (2002) The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochemical Journal 367, 629-640CrossRefGoogle ScholarPubMed
47Liu, M. et al. (2005) Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates. Journal of Biological Chemistry 280, 5588-5597CrossRefGoogle ScholarPubMed
48Payton, S.G. et al. (2007) Effects of 5 untranslated region diversity on the posttranscriptional regulation of the human reduced folate carrier. Biochimica et Biophysica Acta 1769, 131-138Google Scholar
49Flatley, R.M. et al. (2004) Primary acute lymphoblastic leukemia cells use a novel promoter and 5noncoding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Clinical Cancer Research 10, 5111-5122Google Scholar
50Chango, A. et al. (2000) A polymorphism (80G-> A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Molecular Genetics and Metabolism 70, 310-315CrossRefGoogle ScholarPubMed
51Whetstine, J.R. et al. (2001) Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clinical Cancer Research 7, 3416-3422Google Scholar
52Whetstine, J.R., Witt, T.L. and Matherly, L.H. (2002) The human reduced folate carrier gene is regulated by the AP2 and Sp1 transcription factor families and a functional 61 base pair polymorphism. Journal of Biological Chemistry 277, 43873-43880CrossRefGoogle Scholar
53De Marco, P. et al. (2003) Reduced folate carrier polymorphism (80A–>G) and neural tube defects. European Journal of Human Genetics 11, 245-252CrossRefGoogle Scholar
54Morin, I. et al. (2003) Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Molecular Genetics and Metabolism 79, 197-200CrossRefGoogle ScholarPubMed
55Laverdiere, C. et al. (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100, 3832-3834CrossRefGoogle ScholarPubMed
56Matherly, L.H. (2004) Human reduced Folate carrier gene and transcript variants: functional, physiologic, and pharmacologic consequences. Current Pharmacogenetics 2, 287-298Google Scholar
57O'Leary, V.B. et al. (2006) Reduced folate carrier polymorphisms and neural tube defect risk. Molecular Genetics and Metabolism 87, 364-369Google Scholar
58Nakai, Y. et al. (2007) Functional characterization of human PCFT/HCP1 heterologously expressed in mammalian cells as a folate transporter. Journal of Pharmacology and Experimental Therapeutics 322, 469-476CrossRefGoogle Scholar
59Umapathy, N.S. et al. (2007) Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types. Investigative Ophthalmology and Visual Science 48, 5299-5305CrossRefGoogle ScholarPubMed
60Shayeghi, M. et al. (2005) Identification of an intestinal heme transporter. Cell 122, 789-801CrossRefGoogle ScholarPubMed
61Henderson, G.B. and Strauss, B.P. (1990) Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells. Cancer Research 50, 1709-1714Google ScholarPubMed
62Zhao, R. et al. (2004) A prominent low-pH methotrexate transport activity in human solid tumor cells: Contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clinical Cancer Research 10, 718-727CrossRefGoogle Scholar
63Kuhnel, J.M., Chiao, J.H. and Sirotnak, F.M. (2000) Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells. Journal of Cellular Physiology 184, 364-3723.0.CO;2-N>CrossRefGoogle ScholarPubMed
64Sierra, E.E. and Goldman, I.D. (1998) Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochemical Pharmacology 55, 1505-1512CrossRefGoogle Scholar
65Assaraf, Y.G., Babani, S. and Goldman, I.D. (1998) Increased activity of a novel low pH folate transporter associated with lipoplilic antifolate resistance in Chinese hamster ovary cells. Journal of Biological Chemistry 273, 8106-8111CrossRefGoogle Scholar
66Qiu, A. et al. (2007) Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. American Journal of Physiology Cell Physiology 293, C1669-C1678CrossRefGoogle ScholarPubMed
67Zhao, R. et al. (2008) The proton-coupled folate transporter (PCFT): impact on pemetrexed transport and on antifolate activities as compared to the reduced folate carrier. Molecular Pharmacology 74, 854-862CrossRefGoogle Scholar
68Sierra, E.E. et al. (1997) pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells - Further evidence for a third route mediated at low pH. Biochemical Pharmacology 53, 223-231CrossRefGoogle ScholarPubMed
69Wang, Y., Zhao, R. and Goldman, I.D. (2004) Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clinical Cancer Research 10, 6256-6264Google Scholar
70Schron, C.M., Washington, C. Jr. and Blitzer, B.L. (1985) The transmembrane pH gradient drives uphill folate transport in rabbit jejunum. Direct evidence for folate/hydroxyl exchange in brush border membrane vesicles. Journal of Clinical Investigation 76, 2030-2033CrossRefGoogle ScholarPubMed
71Mackenzie, B. et al. (2006) Divalent metal-ion transporter DMT1 mediates both H+ -coupled Fe2+ transport and uncoupled fluxes. Pflugers Archiv (European Journal of Physiology) 451, 544-558CrossRefGoogle Scholar
72Sirotnak, F.M. et al. (1979) Stereospecificity at carbon 6 of formyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochemical Pharmacology 28, 2993-2997CrossRefGoogle ScholarPubMed
73Inoue, K. et al. (2008) Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. American Journal of Physiology Gastrointestinal Liver Physiology 294, G660-G668Google Scholar
74Unal, E.S. et al. (2008) N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT). Biochimica et Biophysica Acta 1178, 1407-1414CrossRefGoogle Scholar
75Yun, C.H. et al. (1995) Structure/function studies of mammalian Na-H exchangers-an update. Journal of Physiology 482 (Suppl.), 1S-6SCrossRefGoogle ScholarPubMed
76McEwan, G.T. et al. (1990) A combined TDDA-PVC pH and reference electrode for use in the upper small intestine. Journal of Medical Engineering and Technology 14, 16-20CrossRefGoogle ScholarPubMed
77Ikuma, M. et al. (1996) Effects of aging on the microclimate pH of the rat jejunum. Biochimica et Biophysica Acta 1280, 19-26CrossRefGoogle ScholarPubMed
78Said, H.M., Smith, R. and Redha, R. (1987) Studies on the intestinal surface acid microclimate: developmental aspects. Pediatric Research 22, 497-499CrossRefGoogle ScholarPubMed
79Yang, J. et al. (2007) Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. Journal of Pharmacology and Experimental Therapeutics 321, 462-468CrossRefGoogle Scholar
80Wang, Y. et al. (2001) Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochimica et Biophysica Acta 1513, 49-54Google Scholar
81Subramanian, V.S., Marchant, J.S. and Said, H.M. (2008) Apical membrane targeting and trafficking of the human proton-coupled transporter in polarized epithelia. American Journal of Physiology Cell Physiology 294, C233-C240Google Scholar
82Mason, J.B. and Rosenberg, I.H. (1994) Intestinal absorption of folate. In Physiology of the gastrointestinal tract (Third edn) (Johnson, L.R., ed.), pp. 1979-1995, Raven PressGoogle ScholarPubMed
83Selhub, J. and Rosenberg, I.H. (1981) Folate transport in isolated brush border membrane vesicles from rat intestine. Journal of Biological Chemistry 256, 4489-4493CrossRefGoogle ScholarPubMed
84Mason, J.B. et al. (1990) Carrier affinity as a mechanism for the pH-dependence of folate transport in the small intestine. Biochimica et Biophysica Acta 1024, 331-335CrossRefGoogle ScholarPubMed
85Kumar, C.K. et al. (1998) Comparison of intestinal folate carrier clone expressed in IEC-6 cells and in Xenopus oocytes. American Journal of Physiology 274, C289-C294Google Scholar
86Chiao, J.H. et al. (1997) RFC-1 gene expression regulates folate absorption in mouse small intestine. Journal of Biological Chemistry 272, 11165-11170Google Scholar
87Chattopadhyay, S. et al. (2006) The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Molecular Cancer Therapeutics 5, 438-449CrossRefGoogle Scholar
88Zhao, R., Hanscom, M. and Goldman, I.D. (2005) The relationship between folate transport activity at low pH and reduced folate carrier function in human Huh7 hepatoma cells. Biochimica et Biophysica Acta 1715, 57-64Google Scholar
89Wang, Y. et al. (2005) Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function. American Journal of Physiology Cell Physiology 288, C65-C71Google Scholar
90Balamurugan, K. and Said, H.M. (2006) Role of reduced folate carrier in intestinal folate uptake. American Journal of Physiology Cell Physiology 291, C189-C193Google Scholar
91Lu, Y. and Low, P. (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Advanced Drug Delivery Reviews 54, 675-693Google Scholar
92Jansen, G. (1999) Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates. (Jackman, A.L. ed.), pp. 293-321, Humana PressGoogle Scholar
93Brigle, K.E. et al. (1994) Increased expression and characterization of two distinct folate-binding proteins in murine erythroleukemia cells. Biochemical Pharmacology 47, 337-345Google Scholar
94Wang, X. et al. (1992) Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochemical Pharmacology 44, 1898-1901Google ScholarPubMed
95Maziarz, K.M. et al. (1999) Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. Journal of Biological Chemistry 274, 11086-11091Google Scholar
96Kamen, B.A. et al. (1988) Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. Journal of Biological Chemistry 263, 13602-13609CrossRefGoogle Scholar
97Rothberg, K.G. et al. (1990) The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. Journal of Cell Biology 110, 637-649Google Scholar
98Kamen, B.A., Smith, A.K. and Anderson, R.G.W. (1991) The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. Journal of Clinical Investigation 87, 1442-1449Google Scholar
99Prasad, P.D. et al. (1994) Functional coupling between a bafilomycin A1-sensitive proton pump and a probenecid-sensitive folate transporter in human placental choriocarcinoma cells. Biochimica et Biophysica Acta Molecular Cell Research 1222, 309-314CrossRefGoogle Scholar
100Andrews, N.C. (2007) When is a heme transporter not a heme transporter? When it's a folate transporter. Cell Metabolism 5, 5-6CrossRefGoogle Scholar
101Sierra, E.E. et al. (1995) Comparison of transport properties of the reduced folate carrier and folate receptor in murine L1210 leukemia cells. Biochemical Pharmacology 50, 1287-1294Google Scholar
102Spinella, M.J. et al. (1995) Distinguishing between folate receptor-α-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. Journal of Biological Chemistry 270, 7842-7849Google Scholar
103Parker, N. et al. (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Analytical Biochemistry 338, 284-293Google Scholar
104Smith, S.B. et al. (1999) Expression of folate receptor alpha in the mammalian retinol pigmented epithelium and retina. Investigative Ophthalmology and Visual Science 40, 840-848Google ScholarPubMed
105Chancy, C.D. et al. (2000) Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. Journal of Biological Chemistry 275, 20676-20684CrossRefGoogle ScholarPubMed
106Toffoli, G. et al. (1997) Overexpression of folate binding protein in ovarian cancers. International Journal of Cancer 74, 193-198Google Scholar
107Kelley, K.M., Rowan, B.G. and Ratnam, M. (2003) Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Research 63, 2820-2828Google Scholar
108Tran, T. et al. (2005) Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Research 65, 4431-4441Google Scholar
109Ratnam, M. et al. (1989) Homologous membrane folate binding proteins in human placenta: Cloning and sequence of cDNA. Biochemistry 28, 8249-8254CrossRefGoogle ScholarPubMed
110Wang, H. et al. (2000) Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood 96, 3529-3536Google Scholar
111Reddy, J.A. et al. (1999) Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood 93, 3940-3948CrossRefGoogle ScholarPubMed
112Ross, J.F. et al. (1999) Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85, 348-357Google Scholar
113Elnakat, H. (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Advanced Drug Delivery Reviews 56, 1067-1084Google Scholar
114Assaraf, Y.G. (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resistance Updates 9, 227-246Google Scholar
115Wielinga, P. et al. (2005) The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Research 65, 4425-4430Google Scholar
116Fry, D.W., Yalowich, J.C. and Goldman, I.D. (1982) Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascited tumor cell in vitro. Journal of Biological Chemistry 257, 1890-1896Google Scholar
117Masuda, M. et al. (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Research 57, 3506-3510Google ScholarPubMed
118Mottino, A.D. et al. (2000) Expression and localization of multidrug resistant protein mrp2 in rat small intestine. Journal of Pharmacology and Experimental Therapeutics 293, 717-723Google ScholarPubMed
119Rost, D. et al. (2002) Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. American Journal of Physiology Gastrointestinal Liver Physiology 282, G720-G726Google Scholar
120Taipalensuu, J. et al. (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. Journal of Pharmacology and Experimental Therapeutics 299, 164-170Google Scholar
121Seithel, A. et al. (2006) Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. European Journal of Pharmaceutical Sciences 28, 291-299Google Scholar
122Koepsell, H. and Endou, H. (2004) The SLC22 drug transporter family. Pflugers Archiv (European Journal of Physiology) 447, 666-676Google Scholar
123Sekine, T., Miyazaki, H. and Endou, H. (2006) Molecular physiology of renal organic anion transporters. American Journal of Physiology. Renal Physiology 290, F251-F261CrossRefGoogle ScholarPubMed
124Hagenbuch, B. and Meier, P.J. (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Archiv (European Journal of Physiology) 447, 653-665CrossRefGoogle ScholarPubMed
125Masuda, S. (2003) Functional characteristics and pharmacokinetic significance of kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the urinary excretion of anionic drugs. Drug Metabolism and Pharmacokinetics 18, 91-103CrossRefGoogle ScholarPubMed
126Rizwan, A.N. and Burckhardt, G. (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharmaceutical Research 24, 450-470Google Scholar
127Uwai, Y. et al. (2004) Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metabolism and Pharmacokinetics 19, 369-374CrossRefGoogle ScholarPubMed
128Takeda, M. et al. (2002) Characterization of methotrexate transport and its drug interactions with human organic anion transporters. Journal of Pharmacology and Experimental Therapeutics 302, 666-671Google Scholar
129Nozaki, Y. et al. (2004) Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. Journal of Pharmacology and Experimental Therapeutics 309, 226-234Google Scholar
130Cha, S.H. et al. (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Molecular Pharmacology 59, 1277-1286Google Scholar
131VanWert, A.L. and Sweet, D.H. (2008) Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates. Pharmaceutical Research 25, 453-462Google Scholar
132Zhao, R. et al. (2001) Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. Journal of Biological Chemistry 276, 10224-10228Google Scholar
133Gelineau-van Waes, J. et al. (2008) Embryonic development in the reduced folate carrier knockout mouse is modulated by maternal folate supplementation. Birth Defects Research Part A Clinical and Molecular Teratology 82, 494-507Google Scholar
134Piedrahita, J.A. et al. (1999) Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nature Genetics 23, 228-232Google Scholar
135Geller, J. et al. (2002) Hereditary folate malabsorption: family report and review of the literature. Medicine 81, 51-68Google Scholar
136Lasry, I. et al. (2008) A novel loss of function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function. Blood 112, 2055-2061CrossRefGoogle ScholarPubMed
137Russell, R.M. et al. (1979) Influence of intraluminal pH on folate absorption: studies in control subjects and in patients with pancreatic insufficiency. Journal of Laboratory and Clinical Medicine 93, 428-436Google ScholarPubMed
138Russell, R.M. et al. (1988) Effect of antacid and H2 receptor antagonists on the intestinal absorption of folic acid. Journal of Laboratory and Clinical Medicine 112, 458-463Google Scholar
139Rosenberg, I.H. et al. (1969) Absorption of polyglutamic folate: participation of deconjugating enzymes of the intestinal mucosa. New England Journal of Medicine 280, 985-988CrossRefGoogle ScholarPubMed
140Butterworth, C.E. Jr., Baugh, C.M. and Krumdieck, C. (1969) A study of folate absorption and metabolism in man utilizing carbon-14–labeled polyglutamates synthesized by the solid phase method. Journal of Clinical Investigation 48, 1131-1142Google Scholar
141Halsted, C.H. (1989) The intestinal absorption of dietary folates in health and disease. Journal of the American College of Nutrition 8, 650-658Google Scholar
142Shafizadeh, T.B. and Halsted, C.H. (2007) gamma-Glutamyl hydrolase not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. Journal of Nutrition 137, 1149-1153CrossRefGoogle Scholar
143Horne, D.W. and Reed, K.A. (1992) Transport of methotrexate in basolateral membrane vesicles from rat liver. Archives of Biochemistry and Biophysics 298, 121-128CrossRefGoogle ScholarPubMed
144Horne, D.W. (1990) Na+ and pH dependence of 5-methyltetrahydrofolic acid and methotrexate transport in freshly isolated hepatocytes. Biochimica et Biophysica Acta Bio-Membranes 1023, 47-55CrossRefGoogle ScholarPubMed
145Horne, D.W., Reed, K.A. and Said, H.M. (1992) Transport of 5-methyltetrahydrofolate in basolateral membrane vesicles of rat liver. American Journal of Physiology Gastrointestinal Liver Physiology 262, G150-G158CrossRefGoogle ScholarPubMed
146Horne, D.W. et al. (1993) 5-Methyltetrahydrofolate transport in basolateral membrane vesicles from human liver. American Journal of Clinical Nutrition 58, 80-84CrossRefGoogle ScholarPubMed
147Arias, I.M. and Forgac, M. (1984) The sinusoidal domain of the plasma membrane of rat hepatocytes contains an amiloride-sensitive Na+/H+ antiport. Journal of Biological Chemistry 259, 5406-5408CrossRefGoogle ScholarPubMed
148Goresky, C.A., Watanabe, H. and Johns, D.G. (1963) The renal excretion of folic acid. Journal of Clinical Investigation 42, 1841-1849Google Scholar
149Selhub, J., Nakamura, S. and Carone, F.A. (1987) Renal folate absorption and the kidney folate binding protein. II. Microinfusion studies. American Journal of Physiology 252, F757-F760Google Scholar
150Selhub, J. and Rosenberg, I.H. (1978) Demonstration of high-affinity folate binding activity associated with the brush border membranes of rat kidney. Proceedings of the National Academy of Sciences of the United States of America 75, 3090-3093Google Scholar
151Selhub, J. et al. (1987) Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. American Journal of Physiology 252, F750-F756Google Scholar
152Birn, H. et al. (2005) Renal tubular reabsorption of folate mediated by folate binding protein 1. Journal of the American Society of Nephrology 16, 608-615CrossRefGoogle ScholarPubMed
153Bhandari, S.D., Joshi, S.K. and McMartin, K.E. (1988) Folate binding and transport by rat kidney brush-border membrane vesicles. Biochimica et Biophysica Acta 937, 211-218Google Scholar
154Bhandari, S.D., Fortney, T. and McMartin, K.E. (1991) Analysis of the pH dependence of folate binding and transport by rat kidney brush border membrane vesicles. Proceedings of the Society for Experimental Biology and Medicine 196, 451-456CrossRefGoogle Scholar
155Jaramillo-Juarez, F., Aires, M.M. and Malnic, G. (1990) Urinary and proximal tubule acidification during reduction of renal blood flow in the rat. Journal of Physiology 421, 475-483Google Scholar
156Santiago-Borrero, P.J. et al. (1973) Congenital isolated defect of folic acid absorption. Journal of Pediatrics 82, 450-455Google Scholar
157Lanzkowsky, P., Erlandson, M.E. and Bezan, A.I. (1969) Isolated defect of folic acid absorption associated with mental retardation and cerebral calcification. Blood 34, 452-465Google Scholar
158Birn, H., Nielsen, S. and Christensen, E.I. (1997) Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule. American Journal of Physiology 272, F70-F78Google Scholar
159Birn, H., Selhub, J. and Christensen, E.I. (1993) Internalization and intracellular transport of folate-binding protein in rat kidney proximal tubule. American Journal of Physiology Cell Physiology 264, C302-C310Google Scholar
160Weitman, S.D., Frazier, K.M. and Kamen, B.A. (1994) The folate receptor in central nervous system malignancies of childhood. Journal of Neuro-Oncology 21, 107-112Google Scholar
161Kennedy, M.D. et al. (2003) Evaluation of folate conjugate uptake and transport by the choroid plexus of mice. Pharmaceutical Research 20, 714-719CrossRefGoogle ScholarPubMed
162Wu, D. and Pardridge, W.M. (1999) Blood-brain barrier transport of reduced folic acid. Pharmaceutical Research 16, 415-419Google Scholar
163Segal, M.B. (2001) Transport of nutrients across the choroid plexus. Microscopy Research and Technique 52, 38-48Google Scholar
164Moretti, P. et al. (2008) Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. Journal of Autism and Developmental Disorders 38, 1170-1177Google Scholar
165Moretti, P. et al. (2005) Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology 64, 1088-1090CrossRefGoogle ScholarPubMed
166Ramaekers, V.T. et al. (2005) Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. New England Journal of Medicine 352, 1985-1991Google Scholar
167Schwartz, R.S. (2005) Autoimmune folate deficiency and the rise and fall of “horror autotoxicus”. New England Journal of Medicine 352, 1948-1950CrossRefGoogle ScholarPubMed
168Ramaekers, V.T. et al. (2007) Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics 38, 276-281Google Scholar
169Spector, R. and Lorenzo, A.V. (1975) Folate transport by the choroid plexus in vitro. Science 187, 540-542CrossRefGoogle ScholarPubMed
170Spector, R. and Lorenzo, A.V. (1975) Folate transport in the central nervous system. American Journal of Physiology 229, 777-782Google Scholar
171Weitman, S.D. et al. (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Research 52, 3396-3401Google Scholar
172Weitman, S.D. et al. (1992) Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Research 52, 6708-6711Google ScholarPubMed
173Selhub, J. and Franklin, W.A. (1984) The folate-binding protein of rat kidney. Purification, properties, and cellular distribution. Journal of Biological Chemistry 259, 6601-6606CrossRefGoogle ScholarPubMed
174Patrick, T.A. et al. (1997) Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. Journal of Neuro-Oncology 32, 111-123Google Scholar
175Segal, M.B. (2000) The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cellular and Molecular Neurobiology 20, 183-196Google Scholar
176Zhao, R. et al. (1997) Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. Journal of Biological Chemistry 272, 21207-21212CrossRefGoogle ScholarPubMed
177Levitt, M. et al. (1971) Transport characteristics of folates in cerebrospinal fluid; a study utilizing doubly labeled 5-methyltetrahydrofolate and 5-formyltetrahydrofolate. Journal of Clinical Investigation 50, 1301-1308Google Scholar
178Maddox, D.M. et al. (2003) Reduced-folate carrier (RFC) is expressed in placenta and yolk sac, as well as in cells of the developing forebrain, hindbrain, neural tube, craniofacial region, eye, limb buds and heart. BioMed Central Developmental Biology 3, 6Google Scholar
179Sweiry, J.H. and Yudilevich, D.L. (1985) Transport of folates at maternal and fetal sides of the placenta: lack of inhibition by methotrexate. Biochimica et Biophysica Acta 821, 497-501Google Scholar
180Sweiry, J.H. and Yudilevich, D.L. (1988) Characterization of folate uptake in guinea pig placenta. American Journal of Physiology 254, C735-C743CrossRefGoogle ScholarPubMed
181Keating, E. et al. (2006) Comparison of folic acid uptake characteristics by human placental choriocarcinoma cells at acidic and physiological pH. Canadian Journal of Physiology and Pharmacology 84, 247-255Google Scholar
182Takahashi, T. et al. (2001) Carrier-mediated transport of folic acid in BeWo cell monolayers as a model of the human trophoblast. Placenta 22, 863-869CrossRefGoogle Scholar
183Poncz, M. et al. (1981) Therapy of congenital folate malabsorption. Journal of Pediatrics 98, 76-79Google Scholar
184Poncz, M. and Cohen, A. (1996) Long-term treatment of congenital folate malabsorption. Journal of Pediatrics 129, 948Google Scholar
185Kim, Y.I. (2004) Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer? Cancer Epidemiol Biomarkers Prev 13, 511-519Google Scholar
186Davey, S.G. and Ebrahim, S. (2005) Folate supplementation and cardiovascular disease. Lancet 366, 1679-1681Google Scholar
187Mischoulon, D. and Raab, M.F. (2007) The role of folate in depression and dementia. Journal of Clinical Psychiatry 68 (Suppl. 10), 28-33Google Scholar
188Ulrich, C.M. and Potter, J.D. (2006) Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 15, 189-193Google Scholar
189Martínez, M.E., Marshall, J.R. and Giovannucci, E. (2008) Diet and cancer prevention: the roles of observation and experimentation. Nature Reviews Cancer 8, 694-703CrossRefGoogle ScholarPubMed
190Eichholzer, M., Tonz, O. and Zimmermann, R. (2006) Folic acid: a public-health challenge. Lancet 367, 1352-1361CrossRefGoogle ScholarPubMed
191Lucock, M. (2000) Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Molecular Genetics and Metabolism 71, 121-138CrossRefGoogle ScholarPubMed
192Kessel, D., Hall, T.C. and Roberts, D. (1965) Uptake as a determinant of methotrexate response in mouse leukemias. Science 150, 752-754Google Scholar
193Hakala, M.T. (1965) On the role of drug penetration in amethopterin resistance of Sarcoma-180 cells in vitro. Biochimica et Biophysica Acta 102, 198-209CrossRefGoogle ScholarPubMed
194Fischer, G.A. (1962) Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells. Biochemical Pharmacology 11, 1233-1234Google Scholar
195Ge, Y. et al. (2007) Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clinical Cancer Research 13, 451-457Google Scholar
196Guo, W. et al. (1999) Mechanisms of methotrexate resistance in osteosarcoma. Clinical Cancer Research 5, 621-627Google Scholar
197Levy, A.S. et al. (2003) Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. Journal of Pediatric Hematology/Oncology 25, 688-695CrossRefGoogle ScholarPubMed
198Zhang, L. et al. (1998) Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clinical Cancer Research 4, 2169-2177Google Scholar
199Zhao, R. et al. (2004) Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Research 64, 3313-3319CrossRefGoogle ScholarPubMed
200Patterson, D. et al. (2008) A humanized mouse model for the reduced folate carrier. Molecular Genetics and Metabolism 93, 95-103Google Scholar
201Veenhoff, L.M., Heuberger, E.H. and Poolman, B. (2002) Quaternary structure and function of transport proteins. Trends in Biochemical Sciences 27, 242-249Google Scholar
202Karlin, A. and Akabas, M.H. (1998) Substituted-cysteine accessibility method. Methods in Enzymology 293, 123-145Google Scholar
203Lemieux, M.J. (2007) Eukaryotic major facilitator superfamily transporter modeling based on the prokaryotic GlpT crystal structure. Molecular Membrane Biology 24, 333-341Google Scholar
204Song, J. et al. (2000) Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Research 60, 5434-5440Google ScholarPubMed
205Song, J. et al. (2000) Chemopreventive effects of dietary folate on intestinal polyps in Apc+/− Msh2−/− mice. Cancer Research 60, 3191-3199Google Scholar
206Kim, Y.I. (2008) Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev. 17, 2220-2225Google Scholar
207Ma, D.W. et al. (2005) Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Research 65, 887-897Google Scholar
208Lawrance, A.K. et al. (2007) Genetic and nutritional deficiencies in folate metabolism influence tumorigenicity in Apcmin/+ mice. Journal of Nutritional Biochemistry 18, 305-312Google Scholar
209Helmlinger, G. et al. (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high- resolution measurements reveal a lack of correlation. Nature Medicine 3, 177-182Google Scholar
210Tredan, O. et al. (2007) Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 99, 1441-1454Google Scholar
211Raghunand, N. et al. (1999) Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochemical Pharmacology 57, 309-312Google Scholar
212Theti, D.S. et al. (2003) Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Research 63, 3612-3618Google ScholarPubMed
213Henderson, E.A. et al. (2006) Targeting the alpha-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase. Bioorganic and Medicinal Chemistry 14, 5020-5042Google Scholar
214Gibbs, D.D. et al. (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Research 65, 11721-11728Google Scholar
215Deng, Y. et al. (2008) Synthesis and Discovery of High Affinity Folate Receptor-Specific Glycinamide Ribonucleotide Formyltransferase Inhibitors with Antitumor Activity. Journal of Medicinal Chemistry 51, 5052-5063Google Scholar
216Zhao, R. et al. (2008) A role for the proton-coupled folate transporter (PCFT - SLC46A1) in folate receptor-mediated endocytosis. Journal of Biological Chemistry Dec 11; [Epub ahead of print]Google Scholar
217Hou, Z. and Matherly, L.H. (2008) Oligomeric structure of the human reduced folate carrier: Identification of homo-oligomers and dominant-negative effects on carrier expression and function. Journal of Biological Chemistry Nov 19; [Epub ahead of print]Google Scholar

Further reading, resources and contacts

For an in-depth up-to-date review of hereditary folate malabsorption from the clinical and genetic perspectives see:

Matherly, L.H., Hou, Z. and Deng, Y. (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer and Metastasis Reviews 26, 111-128Google Scholar
Salazar, M.D. and Ratnam, M. (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer and Metastasis Reviews 26, 141-152Google Scholar
Chattopadhyay, S., Moran, R.G. and Goldman, I.D. (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Molecular Cancer Therapeutics 6, 404-417Google Scholar
Geller, J. et al. (2002) Hereditary folate malabsorption: family report and review of the literature. Medicine 81, 51-68Google Scholar
Figure 0

Figure 1. Structures of representative folate compounds. (a) Folic acid is reduced to dihydrofolic acid at positions 7 and 8 of the B ring, which is in turn reduced to tetrahydrofolic acid at positions 5 and 6 in reactions mediated by dihydrofolate reductase (DHFR). Endogenous folic acid is not found in cells; its presence is related to the consumption of folic acid added to cereals, grains and vitamins. The major oxidised folate in cells is dihydrofolic acid. 5-Methyltetrahydrofolic acid (5-methylTHF) is the major dietary form and the dominant folate found in blood. It is formed endogenously by the reduction of 5,10-methylene-tetrahydrofolic acid (5,10-methyleneTHF). Tetrahydrofolate (THF) is generated upon utilisation of 5-methylTHF in methionine synthesis and 10-formylTHF in purine synthesis. These relationships are depicted in Figure 2. The two carboxyl groups of the glutamate moiety are fully ionised at physiological pH. (b) Structure of 5-methylTHF tetraglutamate, which is one of the 5-methylTHF forms found in nature and in mammalian cells. It is a polyanion and a very poor substrate for folate transporters and multidrug-resistance-associated proteins.

Figure 1

Figure 2. Folate metabolic pathways. 5-MethylTHF enters the metabolic cycle following transport into cells where, with homocysteine, it is utilised in the synthesis of methionine mediated by methionine synthase and vitamin B12. The tetrahydrofolate (THF) product then acquires a carbon from formate or serine, at the N5 or N10 positions, which, through a series of interconversions, results in several other folate forms that provide carbons for purine, thymidylate and methionine synthesis. Abbreviations: AICAR, 5-amino-4-imidazolecarboxamide ribonucleotide; GAR, β-glycinamide ribonucleotide; SHMT, serinehydroxymethyltransferase.

Figure 2

Figure 3. Folate and related transporters and the processes that impact transmembrane folate flows and gradients. (a) Transport mediated by the SLC19 family of solute transporters. Thiamine (T+), a cation, is transported into cells via SLC19A2 and SLC19A3. Within cells, thiamine is metabolised to thiamine pyrophosphate (TPP), an anion, in a reaction mediated by thiamine pyrophosphate kinase (TPK). TPP can be hydrolysed to thiamine monophosphate (TMP), also an anion, mediated by thiamine pyrophosphatase (TPPase). Both are substrates for the reduced folate carrier (RFC; SLC19A1) and are exported by that mechanism. Folates enter cells via RFC and are not substrates for the thiamine transporters. Likewise, thiamine is not a substrate for RFC. (b) Folate transporters. The proton-coupled folate transporter (PCFT) is a folate (Fol)–H+ symporter that functions most efficiently in an acidic extracellular environment. The reduced folate carrier (RFC) is an anion exchanger that utilises the transmembrane organic phosphate (OP) gradient to achieve uphill transport into cells. Folate receptors FRα and FRβ are high-affinity folate-binding proteins that transport folates into cells via an endocytic mechanism. Once in the cytoplasm, the vesicle acidifies, folate is release from the receptor, and is exported from the endosome by a mechanism proposed to be mediated at least in part by PCFT. Folate monoglutamates are exported from cells via the multidrug- resistance-associated proteins (MRPs) and the breast-cancer-resistant protein (BCRP).

Figure 3

Figure 4. Gene structure and membrane topology of the reduced folate carrier. (a) Schematic of the upstream region of SLC19A1, the human gene encoding the reduced folate carrier (RFC). There are six alternative noncoding regions, each preceded by a separate promoter, spanning ∼35 kb upstream of the major translation start site. The alternative promoters transcribe unique RFC transcripts, each with a distinct 5′ untranslated region (5′UTR) fused to a common coding sequence. Alternative splicing for the A1/A2, A, B and D 5′UTRs has been described. For the A1/A2 and A 5′UTRs, upstream AUG start codons occur in-frame within the RFC noncoding sequence and result in N-terminally modified RFC protein isoforms, with 64 and 22 additional N-terminal amino acids, respectively. (b) Membrane topology of the human RFC including 12 transmembrane domains (TMDs), internally oriented N- and C-termini, the large cytosolic loop between TMD6 and TMD7 and the N-glycosylation site at Asn58.

Figure 4

Figure 5. Genomic organisation and predicted secondary structure of the proton-coupled folate transporter and mutations in patients with hereditary folate malabsorption. (a) Genomic organisation of SLC46A1, the gene encoding the proton-coupled folate transporter (PCFT); positions of the various mutations, as reported, in the first to fourth exons are indicated. (b) A schematic of a predicted human PCFT topology showing confirmed N-glycosylation sites (N58, N68) between the first and second transmembrane domains with the N- and C- termini oriented to the cytoplasm. The positions of reported mutations in the protein derived from patients with the autosomal recessive disorder hereditary folate malabsorption (HFM) are indicated.

Figure 5

Figure 6. Intestinal absorption of dietary folates. Dietary 5-methylTHF polyglutamates (Fol-pg) are hydrolysed to monoglutamate (Fol) by glutamate carboxypeptidase II (GCII) and then transported into cells via the proton-coupled folate transporter (PCFT). Both hydrolysis and PCFT-mediated transport have a low pH optimum and are favoured by the low pH within the microenvironment at the jejunal villi (indicated in blue) that is generated by Na+/H+ exchangers (NHE). RFC is expressed at the apical brush-border membrane but, as indicated by the red cross, is not functional at the pH in this region at usual folate dietary levels. Cellular folates exit the basolateral membrane by a mechanism that probably involves a member of the multidrug-resistance-associated protein (MRP) family of ATP-binding-cassette (ABC) exporters.